WO2012132369A1 - 癌幹細胞を標的とするウイルスベクター - Google Patents
癌幹細胞を標的とするウイルスベクター Download PDFInfo
- Publication number
- WO2012132369A1 WO2012132369A1 PCT/JP2012/002031 JP2012002031W WO2012132369A1 WO 2012132369 A1 WO2012132369 A1 WO 2012132369A1 JP 2012002031 W JP2012002031 W JP 2012002031W WO 2012132369 A1 WO2012132369 A1 WO 2012132369A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- promoter
- gene
- virus
- cells
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 450
- 201000011510 cancer Diseases 0.000 title claims abstract description 429
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 262
- 239000013603 viral vector Substances 0.000 title claims abstract description 95
- 230000008685 targeting Effects 0.000 title abstract description 11
- 239000013598 vector Substances 0.000 claims abstract description 116
- 238000000034 method Methods 0.000 claims abstract description 84
- 238000011282 treatment Methods 0.000 claims abstract description 38
- 238000002372 labelling Methods 0.000 claims abstract description 25
- 206010027476 Metastases Diseases 0.000 claims abstract description 15
- 230000009401 metastasis Effects 0.000 claims abstract description 15
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 10
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims description 207
- 102100040120 Prominin-1 Human genes 0.000 claims description 198
- 108090000623 proteins and genes Proteins 0.000 claims description 177
- 241000700605 Viruses Species 0.000 claims description 73
- 238000013518 transcription Methods 0.000 claims description 72
- 230000035897 transcription Effects 0.000 claims description 72
- 241000701161 unidentified adenovirus Species 0.000 claims description 67
- 108020004707 nucleic acids Proteins 0.000 claims description 34
- 102000039446 nucleic acids Human genes 0.000 claims description 34
- 150000007523 nucleic acids Chemical group 0.000 claims description 34
- 230000001472 cytotoxic effect Effects 0.000 claims description 33
- 239000003550 marker Substances 0.000 claims description 33
- 231100000433 cytotoxic Toxicity 0.000 claims description 32
- 239000002773 nucleotide Substances 0.000 claims description 29
- 125000003729 nucleotide group Chemical group 0.000 claims description 29
- 230000001225 therapeutic effect Effects 0.000 claims description 28
- 230000012010 growth Effects 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 230000003612 virological effect Effects 0.000 claims description 15
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 14
- 101150075174 E1B gene Proteins 0.000 claims description 11
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 9
- 230000000174 oncolytic effect Effects 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 239000000032 diagnostic agent Substances 0.000 claims description 8
- 229940039227 diagnostic agent Drugs 0.000 claims description 8
- 244000309459 oncolytic virus Species 0.000 claims description 7
- 230000001629 suppression Effects 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 241000702263 Reovirus sp. Species 0.000 claims description 6
- 241000700584 Simplexvirus Species 0.000 claims description 6
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 5
- 241000709687 Coxsackievirus Species 0.000 claims description 5
- 241000712079 Measles morbillivirus Species 0.000 claims description 5
- 241000711408 Murine respirovirus Species 0.000 claims description 5
- 241000837158 Senecavirus A Species 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 230000000069 prophylactic effect Effects 0.000 claims description 5
- 241000700562 Myxoma virus Species 0.000 claims description 4
- 241000700618 Vaccinia virus Species 0.000 claims description 4
- 239000002257 antimetastatic agent Substances 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 230000000644 propagated effect Effects 0.000 claims description 4
- 230000000840 anti-viral effect Effects 0.000 claims description 3
- 239000012830 cancer therapeutic Substances 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 abstract description 15
- 239000004480 active ingredient Substances 0.000 abstract description 6
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
- 231100000167 toxic agent Toxicity 0.000 abstract 1
- 239000003440 toxic substance Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 288
- 230000000694 effects Effects 0.000 description 90
- 230000001537 neural effect Effects 0.000 description 63
- 230000014509 gene expression Effects 0.000 description 55
- 210000001519 tissue Anatomy 0.000 description 26
- 208000015181 infectious disease Diseases 0.000 description 20
- 238000000684 flow cytometry Methods 0.000 description 17
- 238000003757 reverse transcription PCR Methods 0.000 description 15
- 108020004999 messenger RNA Proteins 0.000 description 14
- 206010009944 Colon cancer Diseases 0.000 description 13
- 208000029742 colonic neoplasm Diseases 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 230000006378 damage Effects 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 230000009385 viral infection Effects 0.000 description 11
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 208000005017 glioblastoma Diseases 0.000 description 9
- 102000044752 human PROM1 Human genes 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- 230000006798 recombination Effects 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 208000003174 Brain Neoplasms Diseases 0.000 description 7
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 7
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 108010005774 beta-Galactosidase Proteins 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 239000013605 shuttle vector Substances 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 206010060862 Prostate cancer Diseases 0.000 description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 6
- 108091023040 Transcription factor Proteins 0.000 description 6
- 102000040945 Transcription factor Human genes 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000005215 recombination Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 5
- 102100026189 Beta-galactosidase Human genes 0.000 description 5
- 108010088225 Nestin Proteins 0.000 description 5
- 102000008730 Nestin Human genes 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 108020004440 Thymidine kinase Proteins 0.000 description 5
- 108090000704 Tubulin Proteins 0.000 description 5
- 102000004243 Tubulin Human genes 0.000 description 5
- 230000022534 cell killing Effects 0.000 description 5
- 238000012790 confirmation Methods 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 201000007270 liver cancer Diseases 0.000 description 5
- 208000014018 liver neoplasm Diseases 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 230000036210 malignancy Effects 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 210000005055 nestin Anatomy 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 102000005908 AC133 Antigen Human genes 0.000 description 4
- 108010005465 AC133 Antigen Proteins 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 108020004459 Small interfering RNA Proteins 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 108010065472 Vimentin Proteins 0.000 description 4
- 102100035071 Vimentin Human genes 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 230000001461 cytolytic effect Effects 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000001902 propagating effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 210000005048 vimentin Anatomy 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 3
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 3
- 108010080611 Cytosine Deaminase Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108700039887 Essential Genes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 239000002771 cell marker Substances 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 3
- 229960004413 flucytosine Drugs 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 229960002963 ganciclovir Drugs 0.000 description 3
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 201000010536 head and neck cancer Diseases 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000009126 molecular therapy Methods 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000001178 neural stem cell Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 2
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 101150029662 E1 gene Proteins 0.000 description 2
- 101710199711 Early E1A protein Proteins 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 102100037102 Homeobox protein MOX-2 Human genes 0.000 description 2
- 101710142888 Homeobox protein MOX-2 Proteins 0.000 description 2
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 2
- 101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 description 2
- 241000598171 Human adenovirus sp. Species 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 108010063954 Mucins Proteins 0.000 description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 2
- 206010034811 Pharyngeal cancer Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 101150027249 RL1 gene Proteins 0.000 description 2
- 206010070308 Refractory cancer Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 108010002687 Survivin Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 102100039094 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 2
- 206010046392 Ureteric cancer Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000011394 anticancer treatment Methods 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 101150046339 fur gene Proteins 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- -1 gefitinib) Chemical class 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000010468 interferon response Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 210000005102 tumor initiating cell Anatomy 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
- 229960002555 zidovudine Drugs 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- KXSKAZFMTGADIV-UHFFFAOYSA-N 2-[3-(2-hydroxyethoxy)propoxy]ethanol Chemical compound OCCOCCCOCCO KXSKAZFMTGADIV-UHFFFAOYSA-N 0.000 description 1
- 101150070234 31 gene Proteins 0.000 description 1
- 102100021501 ATP-binding cassette sub-family B member 5 Human genes 0.000 description 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 description 1
- 108010056962 Adenovirus E4 Proteins Proteins 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000012936 Angiostatins Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 102100027308 Apoptosis regulator BAX Human genes 0.000 description 1
- 108050006685 Apoptosis regulator BAX Proteins 0.000 description 1
- 108090000433 Aurora kinases Proteins 0.000 description 1
- 102000003989 Aurora kinases Human genes 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090001053 Gastrin releasing peptide Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101710094396 Hexon protein Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000677872 Homo sapiens ATP-binding cassette sub-family B member 5 Proteins 0.000 description 1
- 101000827785 Homo sapiens Alpha-fetoprotein Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 101000972286 Homo sapiens Mucin-4 Proteins 0.000 description 1
- 101000693243 Homo sapiens Paternally-expressed gene 3 protein Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 1
- 101000848653 Homo sapiens Tripartite motif-containing protein 26 Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 101100508081 Human herpesvirus 1 (strain 17) ICP34.5 gene Proteins 0.000 description 1
- 101100195053 Human herpesvirus 1 (strain 17) RIR1 gene Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108050009288 Interleukin-19 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 101710176220 Kallikrein-2 Proteins 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000701244 Mastadenovirus Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- 108010092801 Midkine Proteins 0.000 description 1
- 102000016776 Midkine Human genes 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 102100022693 Mucin-4 Human genes 0.000 description 1
- 101000596402 Mus musculus Neuronal vesicle trafficking-associated protein 1 Proteins 0.000 description 1
- 101100521334 Mus musculus Prom1 gene Proteins 0.000 description 1
- 101000706242 Mus musculus Prominin-1 Proteins 0.000 description 1
- 101000800539 Mus musculus Translationally-controlled tumor protein Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101000840556 Oryza sativa subsp. japonica Hexokinase-4, chloroplastic Proteins 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 101150000187 PTGS2 gene Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 102100025757 Paternally-expressed gene 3 protein Human genes 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 101000611641 Rattus norvegicus Protein phosphatase 1 regulatory subunit 15A Proteins 0.000 description 1
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 101000781972 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Protein wos2 Proteins 0.000 description 1
- 241001351225 Sergey Species 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 101100208693 Tetrahymena pyriformis TU20 gene Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 102100037357 Thymidylate kinase Human genes 0.000 description 1
- 101001009610 Toxoplasma gondii Dense granule protein 5 Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 231100000480 WST assay Toxicity 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000001055 blue pigment Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000009421 cellmass formation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 201000008719 cranial nerve neoplasm Diseases 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 108010000742 dTMP kinase Proteins 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 108700020302 erbB-2 Genes Proteins 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 239000001056 green pigment Substances 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 108090000681 interleukin 20 Proteins 0.000 description 1
- 108090000237 interleukin-24 Proteins 0.000 description 1
- 102000003898 interleukin-24 Human genes 0.000 description 1
- 210000003963 intermediate filament Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 210000000441 neoplastic stem cell Anatomy 0.000 description 1
- 206010061311 nervous system neoplasm Diseases 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000033885 plasminogen activation Effects 0.000 description 1
- 108010049148 plastin Proteins 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 150000004579 taxol derivatives Chemical class 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 101150076274 upp gene Proteins 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Definitions
- the present invention relates to a recombinant adenovirus vector having a cancer stem cell-specific promoter.
- the present invention relates to adenoviral vectors that can specifically replicate in cancer stem cells.
- the present invention also relates to a method for identifying cancer stem cells, a method for diagnosing cancer, and a method for treatment using the vector.
- the present invention relates to a diagnostic agent and a therapeutic agent for cancer containing an adenovirus vector as an active ingredient.
- Cancer stem cells are defined as a small number of cancer cells constituting cancer that have the properties of stem cells and have the ability to form tumors. Cancer stem cells have the following characteristics: 1) low division, low proliferation rate, 2) high self-renewal repair ability, 3) maintenance of cancer stem cells by self-replication in cancer tissues, 4) Resistance to anti-cancer drugs and radiation therapy resistance (see Non-Patent Documents 4, 10 and 11). However, if it has stem-like properties, it is not essential to have all the characteristics of 1) to 4), and the main cause of cancer malignancy is an important point. Therefore, it is sometimes referred to as Tumor-Initiating Cell or Cancer Initiating Cell (cancer progenitor cell or tumor or cancer founding cell) (see Non-Patent Document 12).
- cancer stem cells As an important target for cancer treatment, attention has been paid to cancer stem cells as a therapeutic target.
- the cancer stem cell hypothesis has already been proposed in the 1970s, and it has recently been clarified that the presence of cancer stem cells is associated with resistance to cancer treatments, recurrence, and exacerbation.
- the main body of cancer stem cells is also unknown, and research on biological analysis and treatment (especially cancer stem cell-specific treatment) targeting cancer stem cells has hardly progressed.
- CD133 has been reported as a cancer stem cell marker expressed on the cell surface (see Non-Patent Documents 1 to 4).
- Human CD133 was identified as an epitope expressed in CD34 + hematopoietic stem cells in 1997 (see Non-Patent Document 13).
- CD133 is a five-transmembrane glycoprotein called prominin 1 (PROM1), and there are many spliced isoforms whose expression depends on the tissue. The CD133 ligand and downstream signal have not yet been reported, and the function was unknown.
- PROM1 prominin 1
- CD133 is a marker of hematopoietic progenitor cells and vascular endothelial progenitor cells, and at the same time, nervous system tumors (see Non-Patent Documents 1 to 4), prostate cancer (see Non-Patent Document 14), colon cancer (see Non-Patent Documents 5 to 9) ), Lung cancer (see Non-Patent Document 15), and liver cancer (see Non-Patent Documents 16 to 18).
- CD133 has been reported to be expressed in a tissue-dependent manner by at least five types of promoters, but a reporter assay using a human colon cancer-derived cell line Caco-2 cell and a teratocarcinoma cell line NT-2 cell. The results show that promoters 1 and 2 are active, but promoters 3 to 5 were not particularly active (see Non-patent Document 19).
- Caco-2 cell which is a human colon cancer-derived cell line
- Fuji which is a human synovial sarcoma cell line
- promoters 1 to 4 have almost no activity, and promoter 5 It has been reported that there is activity (Non-patent Document 20).
- CD133 promoter activity is enhanced by the enhancer, but not so high promoter activity is recognized.
- Caco-2 cells strongly express CD133, but it is known that the promoter activity of CD133 (particularly promoters 1 to 4) is not so high even when the cells and the pGL3 enhancer vector are used. It was.
- CD133 promoter activity in cancer stem cells has not been known so far.
- promoters specific to cells such as tissues and stem cells are known to have very weak activity compared to promoters used for forced expression such as RSV promoter, CMV promoter, CA promoter and the like.
- promoters used for forced expression such as RSV promoter, CMV promoter, CA promoter and the like.
- RSV promoter CMV promoter
- CA promoter CA promoter
- a virus vector that can be propagated specifically for cancer is known.
- viral vectors include those in which the Rb binding region within the E1 region of adenovirus is deleted (E1A ⁇ 24) or the p53 binding region is deleted (E1B ⁇ 55), or the endogenous promoter of the E1 gene is cancer-specific. Those that are replaced with highly expressed promoters are known.
- an adenoviral vector using a urokinase type plasminogen activation receptor promoter see Patent Document 2
- an adenoviral vector using a PEG3 promoter see Patent Document 3
- an adeno using a survivin promoter A viral vector see Patent Document 4.
- An adenoviral vector capable of cancer-specific growth has oncolytic properties (see Non-Patent Document 22) and is therefore considered effective for cancer treatment.
- the virus amplified in the cancer cells that have been infected / transfected at the time of administration destroys the surrounding cancer cells and further infects the surrounding or remote cancer cells to introduce the gene, the gene must be loaded into the CRA. Therefore, it is considered useful as a gene delivery tool.
- treatment with a viral vector targeting cancer stem cells has also been reported (Non-patent Document 23).
- an object of the present invention is to provide a novel and efficient cancer treatment method targeting cancer stem cells and a method for labeling cancer stem cells.
- the present inventors have conducted intensive studies on promoters that are specifically active in cancer stem cells and can be used for therapeutic and diagnostic purposes. As a result, it is surprising that although the expression of CD133 is comparable or low compared to CaCo-2 cells, the promoter activity of CD133 is very strong in cancer stem cells and can be used for therapeutic and diagnostic purposes as it is. I found it.
- the present inventors have made and examined a vector that grows specifically in cancer stem cells by applying the CD133 promoter to a growth type adenovirus vector (hereinafter referred to as “CRA”).
- CRA growth type adenovirus vector
- CD133-CRA CRA in which the CD133 promoter is operably linked to a nucleic acid encoding a protein essential for viral growth in the viral genome (for example, E1A and E1B) is referred to as a cancer stem cell. It was found to grow specifically. The present inventors have also found that a cancer stem cell-specific proliferation vector infects the cancer stem cell and grows inside the cancer stem cell.
- the vector of the present invention specifically grows in cancer stem cells present in cancer tissue, it can be used to identify cancer stem cells in cancer tissue by inserting a foreign gene to be labeled into the same vector. Furthermore, since the vector of the present invention not only proliferates specifically for cancer stem cells but also maintains the ability to ultimately destroy cancer stem cells, it is useful for treatment targeting cancer stem cells.
- the present invention relates to a promoter that is specifically activated in cancer stem cells and a viral vector having the promoter.
- the present invention also relates to a viral vector that can specifically propagate in cancer stem cells.
- the present invention provides a method for labeling cancer stem cells using the vector, and a method for diagnosing and treating cancer.
- the present invention also provides a cancer stem cell labeling agent containing a vector capable of specifically growing in cancer stem cells as an active ingredient, a cancer diagnostic agent, a metastasis inhibitor, and a therapeutic agent.
- the present invention provides CD133-CRA as a vector that can specifically propagate in cancer stem cells.
- the cancer prevention method, metastasis suppression method, and treatment method are based on the suppression or killing of proliferation of cancer stem cells that are the cause of cancer development.
- the present invention relates to the following inventions: (1) A viral vector having a CD133 promoter operably linked to a desired gene and capable of expressing the desired gene specifically in cancer stem cells. (2) The virus vector according to (1), wherein the desired gene is a gene encoding a protein essential for virus growth and can be propagated specifically in cancer stem cells. (3) The viral vector according to (2), which is oncolytic. (4) Adenovirus, herpes simplex virus, mixoma virus, reovirus, vesicular stoma tytis virus, Newcastle disease virus, vaccinia virus, RS virus, Sendai virus, measles virus, coxsackie virus, or Seneca valley virus The viral vector according to (2) or (3).
- the viral vector according to (2) or (3) which is an adenovirus.
- the adenovirus vector according to (5) wherein the desired gene is an adenovirus E1A or E1B gene.
- E1A is E1A (E1A ⁇ 24) lacking an Rb binding region
- E1B is E1B (E1B ⁇ 55) lacking a p53 binding region.
- the adenovirus vector according to any one of (2) to (7) further comprising a marker gene or a cytotoxic gene.
- the adenoviral vector according to (6) or (7) which is one adenoviral vector selected from the following (a) to (c):
- Adenovirus herpes simplex virus, myxoma virus, reovirus, vesicular stoma tytis virus, Newcastle disease virus, vaccinia virus, RS virus, Sendai virus, measles virus, Coxsackie virus, or Seneca valley virus
- the viral vector according to any one of (11) to (17).
- a cancer therapeutic agent, metastasis inhibitor, prophylactic agent or diagnostic agent comprising the viral vector according to any one of (1) to (19).
- a cancer stem cell labeling agent comprising the viral vector according to any one of (1) to (19).
- a method for labeling cancer stem cells comprising a step of administering the viral vector according to any one of (1) to (19) to a patient in need thereof.
- a method for diagnosing cancer comprising a step of administering the viral vector according to any one of (1) to (19) to a patient in need thereof.
- a method for preventing cancer, a method for suppressing metastasis, or a method for treating cancer comprising a step of administering the virus vector according to any one of (1) to (20) to a patient in need thereof.
- the gene according to any one of (23) to (28), wherein the desired gene is a gene encoding a protein essential for virus growth, and the virus vector can be propagated specifically in cancer stem cells. the method of.
- the CD133 promoter that can be used in the present invention is not particularly limited as long as it is a nucleic acid molecule having a sequence reported as the promoter of CD133 (sometimes called AC133 or PROM1).
- CD133 sometimes called AC133 or PROM1
- mouse, rat, and human CD133 have been reported.
- Shmelkov SV, et al. Blood 2004; 103: 2055-61, and GenBank accession numbers AY275524, AY438641 and AY438640, and human CD133 promoters 1 to 5 can be mentioned.
- the promoter of the present invention includes human CD133 promoter 1 (pr1; SEQ ID NO: 1), promoter 2 (pr2; SEQ ID NO: 2), promoter 3 (pr3; SEQ ID NO: 3), promoter 4 (pr4; sequence) No. 4) and promoter 5 (pr5; SEQ ID NO: 5) can be used.
- CD133 promoters of other animal species for example, mouse Prominin-1 promoter 1 (SEQ ID NO: 6), promoter 2 (SEQ ID NO: 7), or promoter 3 (SEQ ID NO: 8)
- mouse Prominin-1 promoter 1 SEQ ID NO: 6
- promoter 2 SEQ ID NO: 7
- promoter 3 SEQ ID NO: 8
- Kemper K Tol MJPM, Medema JP (2010) Mouse Tissue Express Multiple Split Variants of Prominin-1.PloS ONE 5 (8): e12325
- the “CD133 promoter” is a nucleotide sequence having 85%, 90%, 95%, or 98% homology with the nucleotide sequence described in any one of SEQ ID NOs: 1 to 7 in addition to the above-mentioned promoter.
- a nucleic acid molecule having Sequence homology can be determined, for example, by using BLAST.
- the “CD133 promoter” is a stringent condition with a nucleic acid molecule having the nucleotide sequence set forth in any one of SEQ ID NOs: 1 to 7 or a nucleic acid molecule having a complementary sequence thereto in addition to the above promoter. It may be a nucleic acid molecule that hybridizes with.
- hybridizes under stringent conditions refers to Frederick M. et al. Hybridization is described by the method described in Ausubel et al., “Current Protocols in Molecular Biology” (2011). More specifically, the DNA immobilized on the nitrocellulose membrane is reacted at 65 ° C. in a solution of 0.5 M NaHPO 4 , 7% sodium dodecyl sulfate (SDS), 1 mM EDTA, and then 0.1 to 0 .5 ⁇ SSC (15-30 mM NaCl, 1.5-3 mM sodium citrate, pH 7.0), hybridizing by washing several times at 65-68 ° C. with 0.1% SDS.
- SDS sodium dodecyl sulfate
- the “CD133 promoter” is a nucleic acid in which a part of the nucleotide sequence described in SEQ ID NOs: 1 to 7 is replaced, deleted, or described in any one of SEQ ID NOs: 1 to 7. Includes nucleic acid molecules with additional nucleic acid added to or inserted into the nucleotide sequence. When a nucleic acid is deleted, added, or inserted, a number that does not change the reading frame of the subsequent gene is deleted, added, or inserted. The number of such substitutions, deletions, additions and insertions is 1 to 50 nucleotides, 1 to 20 nucleotides, 1 to 10 nucleotides and 1 to 3 nucleotides.
- substitution, deletion, addition, and insertion Two or more types of mutations may be included among substitution, deletion, addition, and insertion.
- substitution, deletion, addition, or insertion is performed at a position other than the transcription factor binding region.
- the transcription factor binding region can be examined using, for example, a transcription factor binding site prediction program such as TFSEARCH and Aliba, and Shmelkov SV, et al. Blood 2004; 103: 2055-61 (FIG. 3 etc.).
- a nucleic acid molecule in which a part of the nucleotide sequence is substituted, deleted, or an additional nucleic acid is added to or inserted into the nucleotide sequence described in any one of SEQ ID NOs: 1 to 7, is equivalent to CD133 It is desirable to have promoter activity.
- promoter activity equivalent to CD133 means that promoter activity is high under conditions where the activity of the wild-type CD133 promoter is high and activity of the wild-type CD133 promoter is low. Means low.
- the promoter activity equivalent to CD133 mainly means that the promoter activity is qualitatively equivalent to CD133, but the promoter activity equivalent to CD133 is quantitatively equivalent to or more than that of wild-type CD133. May be strong.
- CD133 promoter includes a fragment of the promoter of CD133 as long as the promoter activity equivalent to that of CD133 is maintained.
- the CD133 promoter fragment has at least one transcription factor binding site of the CD133 promoter, and preferably has all of the transcription factor binding sites of the CD133 promoter.
- the transcription factor binding region can be determined by the method described above.
- fragments of the CD133 promoter of the present invention include human CD133 promoter 1 (pr1; SEQ ID NO: 1), promoter 2 (pr2; SEQ ID NO: 2), promoter 3 (pr3; SEQ ID NO: 3), promoter 4 (pr4; SEQ ID NO: 4), and promoter 5 (pr5; SEQ ID NO: 5), and fragments of mouse CD133 promoter 1 (SEQ ID NO: 6), promoter 2 (SEQ ID NO: 7), and promoter 3 (SEQ ID NO: 8).
- CD133 promoter is“ operably linked ”to a desired gene in the viral genome is positioned so that the CD133 promoter can regulate transcription of the gene upstream of the desired gene. Means.
- a “viral vector” is a virus that can incorporate foreign DNA or RNA into a gene, and is not particularly limited as long as it is safe even if administered to a target animal (eg, human).
- the viral vector of the present invention may be either a DNA virus or an RNA virus.
- the viral vector of the present invention is a virus that does not infect cells other than cancer cells (preferably cancer stem cells) or cannot self-replicate in the cells.
- the viral vector is a virus that has oncolytic properties or can acquire oncolytic properties by genetic recombination.
- the viral vector of the present invention preferably has cytolytic properties.
- cytolytic means the ability to lyse the cell and release the virus outside the cell when infected with a cell (for example, a cancer cell or a cancer stem cell) having the conditions for replication of the viral vector.
- a cell for example, a cancer cell or a cancer stem cell
- the virus of the present invention is preferably an oncolytic virus.
- oncolytic virus refers to a virus having the ability to lyse tumor cells.
- the oncolytic virus is toxic to human cancer cells but not normal human cells.
- Viral tumor specificity may be based on any of the viral infection, amplification, and cytolytic properties.
- an oncolytic virus is an animal virus that infects human cancer cells and shows toxicity but does not infect normal human cells and does not show toxicity; a tumor-specific gene whose viral gene promoter is activated only by cancer cells Mutant virus that replicates in cancer cells but does not replicate in normal cells because it is replaced by a promoter; suppresses the cell cycle to create an environment where the cell cycle essential for virus replication is rotating Viruses that inactivate genes (P53, Rb, etc.) are missing or have mutations, so the virus replicates in cancer cells that are rotating with abnormally updated cell cycles, regardless of these mutations.
- the virus vector of the present invention includes herpes simplex virus, mixoma virus, reovirus, vesicular stoma tytis virus, Newcastle disease virus, RS virus, Sendai virus, measles virus, Coxsackie virus, Seneca valley virus.
- herpes simplex virus mixoma virus
- reovirus vesicular stoma tytis virus
- Newcastle disease virus RS virus
- Sendai virus measles virus
- Coxsackie virus Seneca valley virus.
- myxoma virus replicates and causes cell lysis in cancer cells, but does not infect normal human cells.
- reovirus is oncolytic when isolated from nature, and infects both cancer cells and cancer stem cells.
- Vesicular stomatitis virus does not infect normal cells due to an acute antiviral interferon response, but infects cancer cells in which the interferon response has been canceled. Mutant strains and recombinant strains having high oncolytic properties of vesicular stoma tytis virus have been obtained (Lichty, BD et al. (2004) Trends. Mol. Med. 10: 210-216).
- adenovirus or “adenovirus vector” means a virus that belongs to the genus Mast adenovirus belonging to the family Adenoviridae and infects mammals. Preferably, it is a human adenovirus. Although human adenoviruses have sub-genus A to F and serotypes, adenoviruses in the present invention are not limited to specific subgeneras and serotypes.
- the adenovirus may be an adenovirus having a mutation in E1A and / or E1B. Examples of the mutation of E1A protein include deletion of Rb binding region (E1A ⁇ 24). In addition, examples of the mutation of E1B protein include deletion of p53 binding region (E1B ⁇ 55K).
- the “desired gene” is not particularly limited as long as it is a gene that can be used by being specifically expressed in cancer stem cells.
- the desired gene can be a gene encoding a protein essential for virus growth or a cytotoxic gene.
- the desired gene can be a marker gene.
- the “protein essential for virus growth” is not particularly limited as long as it plays a role in virus growth.
- E1A, E1B, E2, E4, L1, L2, L3, L4 and L5 can be mentioned, and E1A and E1B are preferred.
- the protein essential for virus growth may be a wild type or a mutant type.
- the mutant E1A protein includes E1A (E1A ⁇ 24) lacking the Rb binding region.
- Examples of the mutant E1B protein include E1B lacking the p53 binding region (E1B ⁇ 55K).
- the adenoviral vector of the present invention since the vector of the present invention enhances the proliferation of adenovirus in a cell in which the CD133 promoter is activated, the adenoviral vector of the present invention has an E1A ⁇ 24 and / or operably linked to the CD133 promoter. By having E1B ⁇ 55K, the specificity of the proliferation of adenovirus in cancer stem cells can be enhanced.
- a viral vector of the present invention using the herpes simplex virus a protein essential for the growth of virus, ICP34.5 (HSV-1 RL1 gene) and ICP6 (U L 31 gene) can be mentioned .
- Cytotoxic gene refers to a gene that encodes a substance that induces apoptosis or necrosis in the cell by being expressed in the cell, a gene that is phagocytosed by an immune cell by expression, or is expressed in the cell A gene that encodes a substance that stops cell growth.
- the cytotoxic gene may encode a protein or non-coding RNA such as siRNA and miRNA.
- the cytotoxic gene may be one in which the encoded substance itself directly inhibits cell survival or proliferation, or the encoded substance is used together with a prodrug, for example, to poison the prodrug and damage the cell. May be given.
- the cytotoxic gene may be presented on the cell surface and targeted to immune cells such as cytotoxic T cells or antibodies to indirectly kill cells or inhibit proliferation.
- Cytotoxic genes include, but are not limited to, mda-5, mda-7, BAX, PTEN, soluble FGFR, siRNA or antisense to ras, siRNA or antisense to mda-9; HSV-tk Genes that toxicize prodrugs such as (herpes simplex virus-thymidine kinase; ganciclovir is toxic), E.
- coli cytosine deaminase CD; toxic 5-fluorocytosine
- p53 adenovirus E3-11.6K (Ad2 and Ad5-derived), adenovirus E3-10.5K, adenovirus E4 gene, caspase and other pro-apoptotic genes
- p21 retinoblastoma gene, cyclin-dependent kinase inhibitors (p16, p15, p18 and p19) )
- Encoding genes cytostatic genes such as growth arrest-specific homeobox (GAX) genes; cytotoxic genes such as Pseudomonas exotoxins; TNF- ⁇ , p53, APC, DPC-4, BRCA-1, BRCA -2, WT-1, MMAC-1, etc.
- GX growth arrest-specific homeobox
- CEA tumor suppressor genes
- p53 and other antigen genes that are recognized by the immune system on the cell surface
- GM-CSF interferon ⁇ , interferon ⁇ , interferon ⁇ IL-1, IL-2, IL-4, IL-12, IL-10, IL-19, IL-20 and other cytokine genes
- Angiostatin, siRNA or anti-angiogenic genes such as VEGF be able to.
- the cytotoxic gene may be a gene that enhances the responsiveness of radiation therapy, chemotherapy or immunotherapy, for example, EGF receptor (enhancing the therapeutic effect by an EGFR-specific tyrosine kinase inhibitor such as gefitinib), Her-2 receptor (enhancing the therapeutic effect of Herceptin in breast cancer patients) may also be used.
- EGF receptor enhancing the therapeutic effect by an EGFR-specific tyrosine kinase inhibitor such as gefitinib
- Her-2 receptor enhancing the therapeutic effect of Herceptin in breast cancer patients
- the toxic gene is a substance that toxicizes a prodrug, for example, thymidine kinase gene (used in combination with gancyclovir or acyclovir), cytosine deaminase gene (used in combination with 5-fluorocytosine), E. coli-derived upp gene and S. cerevisiae.
- cerevisiae-derived fur gene used in combination with 5-fluorouracil
- thymidine kinase gene or thymidine kinase-thymidylate kinase fusion gene used in combination with azidothymidine
- the “marker gene” refers to a gene that encodes a substance capable of labeling cells into which the gene has been introduced.
- a marker gene capable of labeling cancer stem cells green fluorescent protein (GFP)
- GFP green fluorescent protein
- a gene encoding a fluorescent protein such as EGFP (enhanced GFP), ⁇ -glucuronidase, ⁇ -galactosidase, luciferase, and dihydrofolate reductase.
- GFP green fluorescent protein
- EGFP enhanced GFP
- ⁇ -glucuronidase ⁇ -glucuronidase
- ⁇ -galactosidase ⁇ -galactosidase
- luciferase luciferase
- dihydrofolate reductase dihydrofolate reductase.
- it may be a marker gene that enables image diagnosis, such as a fetishrin gene.
- labeling a cancer stem cell is used to identify the presence or position of a cancer stem cell or a tissue containing a cancer stem cell temporarily or for a long period of time depending on the purpose of use. It means distinguishing from other cells and tissues.
- identifying a cancer stem cell in the present specification means identifying the presence or position of a cancer stem cell or a tissue containing a cancer stem cell temporarily or in the long term, and “identifying” It means that cancer stem cells or tissues containing cancer stem cells are temporarily or long-term distinguished from other cells or tissues.
- the label in this specification is particularly limited as long as it can identify the presence or position of cancer stem cells or tissues containing cancer stem cells, or can distinguish cancer stem cells or tissues containing cancer stem cells from other cells or tissues. It is not required that cells other than cancer stem cells are not stained at all. For example, when the presence of cancer stem cells in a cancer tissue is identified by directly injecting the vector of the present invention into a cancer tissue and staining, the cancer stem cells are distinguished from cancer cells that are not cancer stem cells in the cancer tissue. It only needs to be stained as much as possible, and cancer cells or other cells may be (weakly) stained.
- the viral vector of the present invention has a promoter whose activity is specifically enhanced in cancer cells. It may have a transcription unit (hereinafter referred to as “cancer-specific transcription unit”) operably linked to a different or identical desired gene downstream (hereinafter referred to as “cancer-specific promoter”).
- cancer-specific transcription unit a transcription unit operably linked to a different or identical desired gene downstream
- a function of enhancing the specificity of the toxicity of a virus vector to cancer stem cells by providing a combination of a CD133 promoter transcription unit and a cancer-specific transcription unit, and / or identifying or identifying the toxicity to cancer stem cells and cancer stem cells in one virus vector Can have both.
- a cancer-specific promoter a promoter whose activity is increased in common with many cancers may be used, or a promoter whose expression is specifically increased in the cancer according to the type of target cancer. It may be used.
- the cancer-specific promoter may be a promoter whose activity is enhanced in cancer stem cells.
- cancer-specific promoters include nestin promoter, cyclooxygenase-2 (Cox-2) promoter, multidrug resistance (mdr) protein promoter, telomerase promoter, prostate-specific antigen gene Promoter, kallikrein 2 gene promoter, human ⁇ -fetoprotein gene promoter, melanoma differentiation marker tyrosinase promoter, tyrosinase promoter, c-erbB-2 gene promoter, human carcinoembryonic antigen (CEA) gene promoter, gastrin releasing peptide gene promoter, human telomerase Reverse transcriptase gene promoter, hexokinase II gene promoter, L-plastin gene promoter Motor neuron specific enolase gene promoter, may be mentioned midkine promoter, human mucin genes MUC1 promoter, survivin promoter, Aurora kinase promoter, and the human mucin genes MUC4 promoter.
- nestin promoter cyclooxy
- the virus vector of the present invention may further have an additional transcription unit (hereinafter referred to as “additional transcription unit”) for expressing a desired gene.
- additional transcription unit the promoter controlling the additional transcription unit is not particularly limited as long as it is a promoter active in eukaryotic cells (hereinafter referred to as “eukaryotic cell promoter”).
- eukaryotic cell promoter examples include cytomegalovirus promoter (eg, cytomegalovirus immediate early promoter), Rous sarcoma virus terminal repeat promoter, human elongation factor 1 ⁇ promoter, human ubiquitin c promoter, and PEG-3 promoter. Can be used.
- an inducible promoter such as a mouse breast cancer virus promoter (inducible by dexamethasone), tetracycline-responsive or ecdysone-inducible promoter may be used.
- the aforementioned cancer cell-specific active promoter can also be used.
- a CD133 promoter may be used as a promoter that controls the additional transcription unit.
- the cancer-specific transcription unit and / or the additional transcription unit is a nucleic acid that encodes a protein whose CD133 promoter is essential for viral growth in the viral genome. It may be inserted into the adenovirus E1 region together with a transcription unit operably linked to the adenovirus, or may be inserted into another region of the adenovirus (for example, the E3 region).
- the vector of the present invention has a cancer-specific transcription unit and / or an additional transcription unit, a gene encoding a protein essential for virus growth, a marker gene, or a cytotoxic gene can be used as the desired gene.
- the vector of the present invention may be a multifactor cancer-specific growth control type recombinant adenovirus system (m-CRA; JP 2005-046101 A and International Publication No. WO 2005/012536).
- m-CRA cancer-specific growth control type recombinant adenovirus system
- adenoviral vectors can be cited as examples of adenoviral vectors of the present invention:
- A Adenovirus vector with the following transcription units: (A1) CD133 transcription unit consisting of E133A gene or E1A ⁇ 24 gene operably linked to the CD133 promoter and its downstream (a2) Eukaryotic cell promoter, cancer-specific promoter or CD133 promoter and operably linked to its downstream A transcription unit consisting of an E1B gene or E1B ⁇ 55K gene, or a transcription unit consisting of an E1B ⁇ 19K gene operably linked downstream of a cancer-specific promoter (a3) optionally, a eukaryotic cell promoter, a cancer-specific promoter or a CD133 promoter and An additional transcription unit consisting of a marker gene or cytotoxic gene operably linked downstream thereof;
- B Adenovirus vector with the following transcription units: (B1) a transcription unit consisting of a eukaryotic cell promoter, a cancer-specific promoter or a CD133
- CD133-CRA is a propagating adenoviral vector (CRA) in which the CD133 promoter is operably linked to a nucleic acid encoding a protein essential for viral growth in the viral genome (eg, E1A and E1B), It is synonymous with the adenovirus vector described in the above (a) or (b).
- CRA a propagating adenoviral vector
- virus vector of the present invention may have enhanced specificity for infection to cancer stem cells by modification or substitution of viral fibers or hexons.
- a ligand for a cancer stem cell surface protein may be included in a capsid such as a HI loop of a viral fiber or a hexon protein.
- the vector of the present invention can be specifically labeled or damaged by cancer stem cells, it can be used for the diagnosis, prevention, treatment and cancer metastasis of cancer, or the cancer stem cells can be labeled or damaged. And can be used as a pharmaceutical composition for killing.
- cancers that can be diagnosed, prevented, treated or suppressed in metastasis by the vector of the present invention or a pharmaceutical composition containing the vectors include brain tumors, glioblastomas, head and neck cancers, stomach cancers, lung cancers, breast cancers, uterine cancers, Ovarian cancer, liver cancer, bronchial cancer, nasopharyngeal cancer, pharyngeal cancer, esophageal cancer, bladder cancer, pancreatic cancer, prostate cancer, colon cancer, osteosarcoma, skin cancer, melanoma, thyroid cancer, parathyroid cancer, ureteral cancer, Examples include cervical cancer and hematopoietic or blood malignant tumors (eg, leukemia, malignant lymphoma, etc.).
- a cancer in which the presence of cancer stem cells is confirmed, for example, brain tumor, glioblastoma, head and neck cancer, stomach cancer, lung cancer, breast cancer, liver cancer, bladder cancer, colon cancer, melanoma, pancreatic cancer, prostate cancer, Ovarian cancer (S. Bomken et al., British Journal of cancer (2010) 103: 439-445; Nathasha Y. Frank et al., The Journal of Clinical Investigation (2010) 120: 41-50).
- cancers in which the expression of CD133 is confirmed in cancer stem cells, and examples include brain tumors, breast cancer, prostate cancer, pancreatic cancer, lung cancer, liver cancer, colon cancer, melanoma, prostate cancer (Tabu et al.
- the vector of the present invention or a pharmaceutical composition containing the vector may be used as an agent for identifying, identifying, labeling, injuring or killing cancer stem cells in the cancer.
- “damaging” a cancer stem cell means that the cancer stem cell is unable to exert its function. Specifically, the cancer stem cell self-proliferates and / or differentiates into a cancer cell. It means to make it impossible. “Damage specifically to cancer stem cells” means to give such damage more strongly to cancer stem cells compared to normal cells, and to normal cells or cancer cells other than cancer stem cells. It does not mean that there is no toxicity. Further, “damaging” means that cancer stem cells (including metastatic cancer stem cells) are destroyed by apoptosis or necrosis, cancer stem cells are destroyed by the immune system within the subject, and cancer stem cells Inhibiting proliferation and / or inhibiting differentiation.
- damage to cancer stem cells is caused by the fact that the virus vector of the present invention that can replicate specifically in cancer stem cells and has cytolytic properties (or oncolytic properties) lyses cells (particularly cancer stem cells) after replication in the cells. May be given by Alternatively, the damage to cancer stem cells is caused by the expression of a cytotoxic gene in the cell to induce apoptosis or necrosis in the cell, toxicize the prodrug used together, or presented on the cell surface as an immune cell or antibody It may be given as a target.
- the “injury agent” means an agent that causes such damage to cancer stem cells.
- the present invention includes a cancer stem cell damaging agent containing the viral vector of the present invention as an active ingredient.
- cancer stem cell means a cell that generates a large number of surrounding cancer cells by differentiation while maintaining the cancer stem cell by self-replication in a cancer tissue. Since a small number of cancer stem cells become a large number of cancer cells that form cancer tissue by differentiation, they are sometimes called cancer progenitor cells or tumor or cancer founder cells. As used herein, “cancer stem cell” refers to a cell within a tumor that has the ability to self-renew and provide a heterogeneous lineage of cancer cells, including a tumor (Clark MF et al., Cancer Res. (2006) 66: 9339). -9344).
- cancer stem cells have both the ability to produce daughter cells having the same properties as self and the ability to differentiate into cells that form cancer tissue (particularly malignant tumors). However, this means that it has a stem-like nature to some extent, and it is not necessary to have a strict stem cell characteristic like a normal stem cell (it is not limited to the conditions) Rather, it is important as the main cause of cancer malignancy. Since a small number of cancer stem cells become a large number of cancer cells that form cancer tissues by differentiation, they are sometimes called Tumor-Initiating Cells or Cancer Initiating Cells (cancer progenitor cells or tumor or cancer founding cells).
- the cancer stem cell in the present invention includes these cancer progenitor cells or tumor or cancer founder cells (Neuzil J, et al.
- cancer stem cells may be cells capable of forming cancer when several to tens of thousands (preferably tens to thousands) of cells are transplanted into immunodeficient mice.
- the cancer stem cell in this specification is not limited to this, it is known that the cancer stem cell in solid cancer expresses markers, such as CD24, CD44, CD90, CD133, ABCB5.
- the cancer stem cells of the present invention are brain tumor, glioblastoma, head and neck cancer, stomach cancer, lung cancer, breast cancer, uterine cancer, ovarian cancer, liver cancer, bronchial cancer, nasopharyngeal cancer, pharyngeal cancer, esophageal cancer, bladder cancer, Solid cancers and sarcomas such as pancreatic cancer, prostate cancer, colon cancer, osteosarcoma, skin cancer, melanoma, thyroid cancer, parathyroid cancer, ureteral cancer, cervical cancer, and malignant tumors of hematopoietic organs and blood (eg acute Cancer stem cells of leukemia such as lymphocytic leukemia, malignant lymphoma).
- the cancer stem cells are brain tumor stem cells or glioblastoma stem cells.
- the virus vector of the present invention can express a desired gene specifically for cancer stem cells. Moreover, the therapeutic effect of tumor (cancer stem cell) solubility can be obtained by using the virus vector of the present invention as a proliferating virus that induces cancer growth specific to cancer stem cells. Furthermore, by mounting a marker gene or a therapeutic gene on the viral vector of the present invention, cancer stem cells can be visualized or the therapeutic effect can be induced or enhanced after viral infection. Therefore, by mounting a marker gene or a therapeutic gene on the oncolytic virus vector of the present invention, when cancer stem cells that cause treatment resistance are targeted, the oncolytic effect of the virus or damage is caused by the therapeutic gene. At the same time, the presence of cancer stem cells can be visualized.
- cancer stem cells can be targeted and treated with the viral vector of the present invention itself.
- the virus vector of the present invention capable of selectively identifying cancer stem cells.
- the viral vector of the present invention can visualize, visualize, and identify cancer stem cells that cause malignant transformation with high invasion / metastasis in cancer patients at the time of diagnosis or treatment of cancer patients, and the proportion and location of cancer stem cells.
- Cancer stem cells are resistant to existing treatments such as anticancer drugs and radiation, and the remaining cancer stem cells after treatment lead to cancer recurrence, which is considered to be the main cause of determining poor prognosis and lethality of patients. ing. Therefore, by using the viral vector of the present invention and identifying, visualizing, and detecting cancer stem cells in the body of cancer patients after treatment, a ground-breaking evaluation technique for the effectiveness of treatment methods for cancer patients, It will be possible to establish a revolutionary diagnosis and treatment method that can respond to cancer recurrence after treatment, and to monitor the remaining cancer stem cells after treatment.
- the viral vector of the present invention capable of selectively diagnosing and treating cancer stem cells enables diagnosis of malignant cancer and treatment of the causative cells of malignant malignancy, thereby making a completely new diagnosis and treatment for cancer patients as described above. Many technologies will be produced, and the diagnosis and treatment of cancer will be greatly improved. Therefore, the viral vector of the present invention can be used for diagnosis and treatment targeting various cancer stem cells, and can achieve the cure of clinically refractory cancer and the prevention of recurrence.
- the numerical value (%) in the left figure shows the ratio of the number of cells contained in the elliptical middle cell population indicated by R1 to the total number of cells.
- the right figure shows the CD133 (+) cell content in the R1 cell population.
- the horizontal axis (PE Log) indicates the CD133 (+) cell content
- the vertical axis (FITC Log) has no particular meaning.
- the numerical value in the right figure (CD133 (+) 20.18%) indicates the ratio of CD133 (+) cells to the R1 cell population.
- the upper row shows the results using IgG antibody as a negative control, and the lower row shows results using anti-CD133 antibody.
- the vertical axis shows data by side scattered light, and reflects cell morphology, cell internal structures such as nuclei and granules.
- the numerical value (%) in the figure indicates the ratio of the number of cells contained in the cell population surrounded by the square to the total number of cells.
- the photograph shows the result of electrophoresis after performing the RT-PCR method, and the graph shows the result of quantitative RT-PCR.
- HPRT indicates the housekeeping gene HPRT used as a control gene.
- the vertical axis of the graph represents the ratio of the expression level of CD133 mRNA to the expression level of HPRT mRNA.
- CD133-expressing positive and negative cells were separated from X01GBS cells, which are enriched fractions of human neuronal cancer stem cells, and the CD133 mRNA expression level in each fraction was determined by RT-PCR and quantitative RT-PCR. The results of the investigation are shown.
- the upper left figure shows the fractions sorted by the cell sorter.
- CD133 ( ⁇ ) represents a fraction of CD133 expression negative cells
- CD133 (+) represents a fraction of CD133 expression positive cells.
- the lower left photograph shows the result of electrophoresis after the RT-PCR method.
- the lower right graph shows the results of quantitative RT-PCR.
- HPRT indicates the housekeeping gene HPRT used as a control gene.
- the vertical axis of the graph represents the ratio of the expression level of CD133 mRNA to the expression level of HPRT mRNA.
- a schematic diagram and names of reporter assay adenovirus vectors for measuring the activity of each promoter of CD133 are shown. LacZ was ligated downstream of each promoter of CD133 and incorporated into an adenovirus vector (pAdHM4) lacking the E1 region ( ⁇ E1). The activity of each promoter of CD133 in human neuronal cancer stem cell X01GBS is shown.
- the vertical axis represents ⁇ -galactosidase activity (promoter activity), and the horizontal axis represents the type of adenovirus incorporating each promoter used for LacZ expression.
- pr1, pr2, pr3, pr4, and pr5 indicate CD133 promoter 1, promoter 2, promoter 3, promoter 4, and promoter 5 in this order (the same applies to the following figures).
- the activity of each promoter of CD133 in human neuronal cancer stem cell X01GBS cell is shown.
- the vertical axis represents ⁇ -galactosidase activity (promoter activity)
- the horizontal axis represents the type of adenovirus incorporating each promoter used for LacZ expression.
- the activity of each promoter of CD133 is shown in X01GBD cells of a fraction enriched with cancer cells differentiated from human neuronal cancer stem cells.
- the vertical axis represents ⁇ -galactosidase activity (promoter activity), and the horizontal axis represents the type of adenovirus incorporating each promoter used for LacZ expression.
- promoter activity promoter activity
- the horizontal axis represents LacZ activity (CD133 promoter activity)
- the vertical axis represents CD133 (+) cells with anti-CD133 antibody labeled with PE.
- the numerical value (%) shown in FIG. 6 indicates the proportion of cells correlated in the upper right region R7.
- the figure which compared each promoter activity of CD133 and the activity of the non-specific RSV promoter for control in human neuronal cancer stem cell X01GBS cell is shown.
- the horizontal axis represents LacZ activity (CD133 promoter activity), and the vertical axis represents side scattered light (Side Scatter: SS).
- the numerical value (%) shown in FIG. 12 indicates the ratio of LacZ-expressing cells included in the area surrounded by the square to the total number of cells.
- the figure which compared each promoter activity of CD133 in the X01GBD cell of the fraction which concentrated the human neuronal cancer stem cell X01GBS cell and the cancer cell differentiated from the human neuronal cancer stem cell is shown.
- the horizontal axis represents LacZ activity (CD133 promoter activity), and the vertical axis represents side scattered light (Side Scatter: SS).
- the numerical value (%) shown in FIG. 13 shows the ratio of LacZ-expressing cells contained in the area surrounded by a square to the total number of cells.
- the structure of a proliferation type adenovirus vector specific for cancer stem cells (represented by CD133-reactive m-CRA “Ad.hCD133pr5-m-CRA”, the same applies hereinafter) is shown.
- CD133pr1-5 means any one of CD133 promoters 1-5.
- transduction efficiency in a human neuronal cancer stem cell X01GBS cell is shown.
- FIG. 16 A photograph 24 hours after the infection of X01GBS cells with a non-proliferating adenovirus vector (Ad.CA-EGFP) is shown.
- EGFP is a photograph in which the expression of EGFP is detected
- Phase is a micrograph
- Merge is a photograph in which the above two types of photographs are synthesized and shows the intracellular expression of EGFP ( The same applies to FIG. 16).
- the numerical value of the upper part of a figure shows the observed magnification.
- the cell killing effect of hCD133pr5-m-CRA on human neural cancer stem cells X01GBS cells is shown in cell morphology.
- Ad FIG.
- FIG. 2 shows the results of hCD133pr5-m-CRA infection with X01GBS at MOI 1 and observation with a 200-fold microscope 1, 2, 3, 4 and 5 days after infection.
- the numerical value (Day) at the top of the figure indicates the number of days that have passed since infection.
- CPE at the bottom of the figure indicates a cytopathic effect
- Sphere means the degree of cell mass formation.
- Ad In human neuronal cancer stem cells X01GBS cells. 2 is a graph showing the cell killing effect of hCD133pr5-m-CRA in terms of the number of viable cells.
- the results of measurement of the number of viable cells on day 5 after infection of RSV-dE1.3 with human neuronal cancer stem cells X01GBS at MOIs 1, 3, and 10 are shown.
- the vertical axis represents the ratio (%) of the number of viable cells compared to the untreated group, and the horizontal axis represents the virus infection condition (MOI).
- Ad In X01GBD of a fraction enriched with human neuronal cancer stem cells X01GBS cells and cancer cells differentiated from human neuronal cancer stem cells. 2 is a graph showing the cell killing effect of hCD133pr5-m-CRA in terms of the number of viable cells.
- the vertical axis represents the ratio (%) of the number of viable cells compared to the untreated group
- the horizontal axis represents the virus infection condition (MOI).
- 1 ⁇ 10 6 and 1 ⁇ 10 5 X01GBS cells were transplanted subcutaneously in 4 locations of NOD / SCID immunodeficient mice and 1 ⁇ 10 6 differentiated X01GBD cells were subcutaneously transplanted in 3 locations of NOD / SCID immunodeficient mice, 10 weeks later
- the results of evaluating the rate of formation of tumor nodules that can be visually recognized are shown.
- the vertical axis of the graph indicates tumor volume (mm 3 ), and the horizontal axis indicates the type and number of transplanted cells.
- the three types of photographs all show the results of NOD / SCID immunodeficient mice transplanted with 1 ⁇ 10 6 cells (right) and 1 ⁇ 10 5 cells (left) of X01GBS cells.
- the bottom photo is a tumor mass collected from each mouse.
- the viral vector of the present invention can be produced by appropriately adopting a viral vector production method known to those skilled in the art.
- a viral vector can be prepared by recombination of a viral backbone plasmid having an almost complete copy of the viral genome and a shuttle vector plasmid having a CD133 transcription unit using genetic recombination techniques. Genetic recombination uses homologous recombination, recombination using restriction enzyme sites (preferably, special restriction enzyme sites such as l-CeuI and Pl-SceI), or recombination reaction (for example, Cre-LoxP). It can also be done by recombination.
- the viral vector of the present invention is an adenovirus
- it is prepared by recombining an adenovirus backbone plasmid having an almost complete copy of the adenovirus genome and lacking the E1 gene, and a shuttle vector plasmid having a CD133 transcription unit. be able to.
- the viral vector of the present invention has a cancer-specific transcription unit and / or an additional transcription unit
- the viral vector is a single shuttle vector plasmid having a CD133 transcription unit, a cancer-specific transcription unit and / or an additional transcription unit.
- Each plasmid can be prepared individually by using a shuttle vector plasmid having a CD133 transcription unit and a different cancer-specific transcription unit and / or an additional transcription unit. Alternatively, or simultaneously, it may be prepared by recombination with an adenovirus backbone plasmid.
- a shuttle vector plasmid different from the shuttle vector plasmid having the CD133 transcription unit is used. It is desirable to perform the recombination separately from the shuttle vector plasmid having the E1 region of the adenovirus (such as the E3 region).
- the modified and substituted vector can be prepared by methods well known to those skilled in the art.
- the viral vector of the present invention is an adenovirus
- such viral vectors include Krasnykh et al., Cancer Res (2000) 60 (24): 6784-6787, Ruigork et al. Mol. Biol. (1990) 215: 589-596, Krasnyk et al., J. MoI. Virol. (1996) 70: 6839-6846, Henry et al., J. MoI. Virol. (1994) 68 (6): 5239-6846, and can be prepared according to the method described in International Publication No. WO00 / 67576.
- the present invention comprises a viral vector having a CD133 promoter operably linked to a gene encoding a protein essential for viral growth of the viral vector of the present invention and / or a cancer vector capable of specifically growing, and / or
- the present invention relates to a method for treating cancer, a method for preventing cancer, and a method for suppressing metastasis, including administering a viral vector having a cytotoxic gene (hereinafter collectively referred to as “therapeutic viral vector”) to a patient in need thereof. Since the therapeutic viral vector of the present invention can damage cancer stem cells from which cancer cells are generated, by administering such viral vectors to cancer patients or patients who are expected to become cancerous. Cancer can be treated or prevented, or cancer metastasis can be suppressed.
- an example of the present invention includes administering a therapeutic viral vector to a patient in need thereof, thereby propagating the viral vector in the patient's cancer stem cells or expressing a cytotoxic gene. It is a cancer treatment method, prevention method, or metastasis suppression method.
- Administration of the therapeutic viral vector of the present invention can be appropriately selected depending on the vector to be used, the disease to be treated, age, sex, route of administration, purpose of use, etc.
- 1 ⁇ 10 5 to 1 ⁇ 10 12 pfu Can be administered.
- the administration method includes intratumoral instillation, intravascular (intravenous, intraarterial) injection, intrameningeal injection, intramuscular injection, intradermal injection, subcutaneous injection, transmucosal administration (such as lung), nasal administration, etc. can do.
- the vector of the present invention can be administered 1 ⁇ 10 10 pfu once every 2 days for 5 days.
- the therapeutic viral vector of the present invention may be used in combination with other anticancer treatments. Since the therapeutic viral vector of the present invention treats cancer stem cells as a target, such anti-cancer treatment includes chemotherapy, radiotherapy, immunotherapy, surgical treatment and the like. Examples of the anticancer agent for combined treatment include taxol derivatives such as cisplatin, adriamycin, doxorubicin, and paclitaxel. When the therapeutic viral vector of the present invention has a cytotoxic gene that toxicizes the prodrug, an appropriate prodrug is used in combination.
- prodrugs examples include gancyclovir or acyclovir (thymidine kinase gene), 5-fluorocytosine (cytosine deaminase gene), 5-fluorouracil (upper gene derived from E. coli and fur gene derived from S. cerevisiae), and azidothymidine (thymidine kinase) Gene or a fusion gene of thymidine kinase and thymidylate kinase) (in the parentheses indicate the cytotoxic genes to be combined).
- gancyclovir or acyclovir thymidine kinase gene
- 5-fluorocytosine cytosine deaminase gene
- 5-fluorouracil upper gene derived from E. coli and fur gene derived from S. cerevisiae
- azidothymidine thymidine kinase
- the present invention includes a method for damaging cancer stem cells comprising the step of administering a therapeutic viral vector to a subject in need thereof.
- An example of the present invention is a cancer comprising administering a therapeutic viral vector to a patient in need thereof, thereby propagating the viral vector in the patient's cancer stem cells or expressing a cytotoxic gene. This is a method for damaging stem cells.
- the cancer stem cell injury method of the present invention can be carried out in accordance with the aforementioned method for treating and / or preventing cancer of the present invention.
- the present invention relates to a method for diagnosing cancer, comprising administering to a subject patient a virus vector having a marker gene (hereinafter referred to as “labeling virus vector”) among the virus vectors of the present invention, or
- labeling virus vector a virus vector having a marker gene (hereinafter referred to as “labeling virus vector”) among the virus vectors of the present invention, or
- the present invention relates to a method for labeling cancer stem cells. Since the labeling virus vector of the present invention can specifically express a marker gene in cancer stem cells, cancer stem cells are administered by administering such virus vectors to cancer patients or patients who are expected to become cancerous. Can be identified or identified. Since cancer stem cells are known to be present in several to several tens of percent in cancer cells, cancer can be diagnosed using the presence of cancer stem cells as an indicator.
- the present invention relates to a method for diagnosing cancer or a method for labeling cancer stem cells, which comprises administering a virus vector for labeling to a target patient and detecting an expression product of the marker gene.
- the detection of the expression product of the marker gene can be appropriately selected depending on the type and purpose of the marker gene to be used. For example, the dye or fluorescent dye may be visually confirmed during surgery, or detected by image diagnosis. May be.
- the diagnosis of cancer or the labeling of cancer stem cells may be performed by visualizing the cancer stem cells, or may be performed by a technique that can be detected by means other than vision.
- the method for diagnosing cancer or the method for labeling cancer stem cells of the present invention may be a method for visualizing cancer stem cells, comprising administering a virus vector for labeling to a target patient.
- the administration can be performed by administering the viral vector for labeling of the present invention, or administering the viral vector of the present invention to a patient according to the method for treating or preventing cancer of the present invention described above.
- compositions comprising the viral vector of the present invention as an active ingredient is an active ingredient.
- a pharmaceutically acceptable carrier may be any generally known carrier that can be sterilized and administered to humans, and examples thereof include physiological saline. Sterilized water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and combinations thereof.
- the pharmaceutical composition may further contain an antioxidant, a buffering agent and a bacteriostatic agent.
- the pharmaceutical composition may be an injectable preparation that can be adjusted.
- the pharmaceutical composition (pharmaceutical composition kit) may contain a diluent, a dispersant, a surfactant, a binder, and a lubricant.
- Example 1 Confirmation of Cancer Stem Cellity of Human Neuronal Cancer Stem Cells and Expression of Cancer Stem Cell Surface Marker CD133 by Cellular Immunostaining
- Cells As human neurocancer stem cells, Soeda A, et al. Human glioblastoma stem cells described in J Biol Chem 2008; 283; 10958-66 were used.
- X01GBS cells are cancer stem cell fractions of X01GB cells, and are a group of cells in which the cancer stem cell fraction has been “enriched” using an undifferentiated medium and a Sphere culture method. Therefore, unless otherwise specified, human neural cancer stem cell X01GBS is hereinafter referred to as Soeda A, et al.
- Neuronal cancer stem cells X01GBS were B-27 (Invitrogen), recombinante human FGF-2 (20 ng / ml; R & D Systems, Minneapolis, MN) and recombinant human EGF (20 ng / ml); The cells were cultured in a Dulbecco's modified Eagle's medium / F-12 (D6421, Sigma) medium containing FBS, penicillin G, and streptomycin sulphate at 37 ° C. with 5% CO 2 .
- Dulbecco's modified Eagle's medium / F-12 D6421, Sigma
- X01GBS cell culture was performed under the same conditions.
- X01GBD cells were established from the X01GBS cells, which are a group of cells enriched with these human neuronal cancer stem cells (glioblastoma-derived cancer stem cells; human glioblastoma stem cells) by the following method. “Neuronal cancer cells” (differentiated glioblastomas) were produced as enriched cells.
- X01GBD cells were obtained from Inagaki A, et al. It was established and maintained according to the establishment method described in Biochem Biopys Res Commun 2007; 361; 586-592 and the maintenance culture method in a differentiated state.
- X01GBS cells were added to 10% fetal bovine serum Fetal bovine serum and Dulbecco's modified Eagle's medium / F-12 medium in which FGF-2 was removed. By culturing and maintaining this for a long time (over 50 passages or more), the cancer stem cell fraction was dramatically reduced, and most of the differentiated cancer cell fractions were replaced with X01GBD cells. .
- the properties of X01GBD cells are described in Inagaki A, et al. Biochem Biopys Res Commun 2007; 361; 586-592.
- the X01GBS cell group of the cancer stem cell fraction with high malignancy and high undifferentiation and the differentiated X01GBD cell group with low malignancy were established from human cranial nerve malignant tumor which is the same tissue of the same patient.
- Anti-nestin rabbit polyclonal antibody (Chemicon, Temecula, CA) Anti-Vimentin rabbit polyclonal antibody (Ab45939, Abcam, UK) Anti-CD133 rabbit polyclonal antibody (Ab19988, Abcam, UK) Anti- ⁇ III tubulin (Tuj1) mouse monoclonal antibody TU20 (Ab7751, Abcam, UK)
- Second antibody The following antibody conjugated with a green fluorescent dye having a wavelength of 488 nm was used as the second antibody: Alexa fluorophore-conjugated 488 (mouse / rabbit, Molecular Probes, Invitrogen)
- the fixed cells were washed with 1 ⁇ PBS, and the first antibody was added to the cells and allowed to react at room temperature for 1 hour. After the reaction, the plate was washed with 1 ⁇ PBS, the second antibody was added so as to have the above-mentioned dilution ratio, reacted at room temperature for 30 minutes, and then washed with PBS.
- DAPI staining When one drop of Mounting Medium with DAPI (H-1500, Vector laboratories, Inc., USA) was added to cells that had been subjected to cell immunostaining at room temperature, cell nuclei were immediately stained.
- Mounting Medium with DAPI H-1500, Vector laboratories, Inc., USA
- Stained cell fluorescence images were obtained from an inverted fluorescence microscope Axio Observer. With a filter set suitable for FITC or DAPI detection. Taken on A1 (Carl Zeiss). The observation results are shown in FIG.
- the upper right figure is a photograph in which protein expression of each cancer stem cell and neuronal marker (name is shown in the figure) is detected by FITC
- the upper left figure is a photograph in which the nucleus is detected by DAPI
- the lower left figure Is a photograph of a phase difference image (without fluorescence)
- the lower right is a photograph of an image obtained by superimposing these three kinds of photographs.
- Nestin is an intermediate filament of class VI and is one of the important markers of neural stem cells that have been reported to be strongly expressed in neural stem cells in the midbrain. Vimentin is a mesenchymal cell marker that has been reported to be expressed only during development. ⁇ III tubulin (Tuj1) has been reported to be a protein that forms the framework of nerve cells, and is used as a marker for nerve cells because gene expression is mainly observed in nerve cells. DAPI is a fluorescent dye that stains nuclei blue. As shown in FIG. 1, the human neural cancer stem cell X01GBS used in this experiment is stained with antibodies against the neural stem cell markers nestin and vimentin, but not with an antibody against ⁇ III tubulin, which is a mature neural cell marker. From this, it was shown that it has stem cell nature. Moreover, since the human neuronal cancer stem cell X01GBS used in this experiment was stained with an antibody against CD133, it was confirmed that CD133 was expressed.
- Example 2 Confirmation of expression of cancer stem cell surface marker CD133 of human neuronal cancer stem cell X01GBS by Western blotting.
- Cells Human neural cancer stem cells X01GBS, colon cancer cells (Caco-2) and human iPS cells (201B7, purchased from RIKEN) were used as positive controls.
- a 10% polyacrylamide gel (196-12921, Wako), and electrophoresis was performed.
- the membrane was removed from the transfer device, immersed in a blocking buffer (5% non-fat dry milk, 10 mM Tris (pH 7.5), 100 mM NaCl, 0.1% Tween 20), and blocked by shaking at room temperature for 1 hour. After removing the blocking buffer, a primary antibody reaction solution diluted 1: 1000 with the blocking buffer was added, and the membrane was reacted by shaking at room temperature for 1 hour.
- a blocking buffer 5% non-fat dry milk, 10 mM Tris (pH 7.5), 100 mM NaCl, 0.1% Tween 20
- wash buffer (10 mM Tris (pH 7.5), 100 mM NaCl, 0.1% Tween 20) was added, and the membrane was washed three times for 15 minutes at room temperature while shaking the membrane.
- the wash buffer was removed, a secondary antibody reaction solution diluted 2000 times was added, and the mixture was allowed to react at room temperature for 1 hour while shaking the membrane.
- the secondary antibody reaction solution was removed, wash buffer was added, and the membrane was washed 3 times for 15 minutes at room temperature while shaking the membrane.
- 0.125 mL / cm 2 of chemiluminescence reaction solution Chemi-Lumi One (05027-20, Wako) was added to the membrane, allowed to react for 1 minute, and then exposed to detect protein expression.
- Figure 3 shows typical results of the experiments conducted.
- the horizontal axis (PE Log) indicates CD133 (+) cells as logarithmic values
- the vertical axis (FITC Log) has no particular meaning.
- the ratio of CD133 (+) cells to the total number of X01GBS cells was about 10 to 20.18%. This indicates that about 10-20% of human neuronal cancer stem cells X01GBS express CD133 on the cell surface.
- Example 4 Analysis of CD133 expression in X01GBS cells and X01GBD cells by flow cytometry X01GBS cells, which are enriched fractions of human neuronal cancer stem cells, and X01GBD cells, which are fractions enriched from differentiated cancer cells, show CD133 expression. Flow cytometry was performed simultaneously with a positive cell line Caco-2 cell (colon cancer) and a CD133 negative cell normal WI-38 cell (fibroblast).
- Figure 4 shows typical results of the experiments conducted.
- the upper graph shows the results of flow cytometry performed using an anti-CD133 antibody, using the IgG antibody as a negative control of the experiment for evaluating the characteristics of the antibody.
- Only 0.5% of CD01GBD cells were positive for CD133 as compared to 4.2% of CD01GBS cells showing CD133 positive, so it became clear that CD133 cell positive cells were enriched in X01GBS cells.
- the ratio of CD133 positive cells in X01GBS cells is slightly different from that in FIG. 3 because the experimental conditions (how to correct fluorescence between target cells in the flow cytometer, the difference in the vertical axis / side population in FIG. This was thought to be due to slight differences between the settings and the like in each experiment.
- Example 5 Analysis of CD133 mRNA expression in X01GBS cells and X01GBD cells X01GBS cells that are enriched fractions of human neural cancer stem cells, X01GBD cells that are fractionated from differentiated cancer cells, and WI-38 that are normal cells The expression level of CD133 mRNA in the cells was examined by electrophoresis after RT-PCR and quantitative RT-PCR. The housekeeping gene HPRT was used as a control gene for RT-PCR.
- Figure 5 shows the experimental results.
- X01GBS cells show significant CD133 mRNA expression in RT-PCR electrophoresis photographs, as opposed to normal WI-38 cells and X01GBD cells. No expression could be detected in the cells.
- quantitative RT-PCR high levels of CD133 mRNA expression were observed in X01GBS cells, whereas CD133 mRNA expression levels in X01GBD cells were extremely low, with statistically significant differences (P ⁇ 0. 0005) was confirmed.
- Example 6 CD133 mRNA expression analysis in X01GBS cells and X01GBD cells Further, X01GBS cells, which are enriched fractions of human neuronal cancer stem cells, were separated into positive and negative cells of CD133 expression using a cell sorter. In the same manner, CD133 mRNA expression level was similarly examined by RT-PCR and quantitative RT-PCR.
- Figure 6 shows typical results.
- the upper left figure shows the fractions sorted by the cell sorter.
- the lower left figure shows the results of RT-PCR, and the lower right figure shows the results of quantitative RT-PCR.
- CD133 mRNA is highly expressed with a statistically significant difference (P ⁇ 0.005) in the fraction obtained by sorting CD133-positive cells. Was confirmed.
- Example 7 Measurement of CD133 Promoter Activity in Human Neuronal Cancer Stem Cell X01GBS ( ⁇ -gal Assay)
- Construction of adenovirus vector for CD133 promoter activity analysis As for human CD133, five types of promoters are known, and promoter 1 (pr1; SEQ ID NO: 1) and promoter 2 (pr2; SEQ ID NO: 2), respectively. , Promoter 3 (pr3; SEQ ID NO: 3), promoter 4 (pr4; SEQ ID NO: 4), and promoter 5 (pr5; SEQ ID NO: 5) (Sergey V. Shemelkov et al., BLOOD, 15 MARCH 2004, Vol. 103, No. 6).
- LacZ was linked downstream of five human CD133 promoters and incorporated into a non-proliferating adenovirus vector lacking the E1 region.
- An adenovirus vector was constructed.
- a vector in which LacZ is ligated downstream of pr1 and incorporated into an adenoviral vector is referred to as “Ad.hCD133pr1-LacZ”.
- a product in which LacZ is ligated downstream of pr2 to pr5 is added to ⁇ E1 of the adenoviral vector.
- the incorporated vectors are referred to as “Ad.hCD133pr2-LacZ”, “Ad.hCD133pr3-LacZ”, “Ad.hCD133pr4-LacZ”, and “Ad.hCD133pr5-LacZ”, respectively. These vectors are collectively referred to as “Ad.hCD133pr1-5-LacZ”.
- the vector construction method is described in Chen SH, et al. (1995) PNAS 92 (7): Constructed with reference to the method described in 2577-2581.
- adenoviral vector Ad.hCD133pr1-5-LacZ constructed as described above was infected with the number of viruses MOI (multiplicity of infection) per cell.
- MOI multiplicity of infection
- Human neuronal cancer stem cells X01GBS were infected with MOI 30.
- the activity of each promoter of human CD133 was measured using a beta-galactosidase enzyme assay system (Promega, USA) according to the manufacturer's attached protocol.
- promoters 1, 2, 4, and 5 are high in activity, and among them, promoter 5 is the most in human neuronal cancer stem cell X01GBS. It was shown to have high transcription activity.
- FIG. 9 The average values and standard errors of the experimental results are shown in FIG. 9 (X01GBS cells) and FIG. 10 (X01GBD cells).
- X01GBS cells various activities were observed in all promoters in X01GBS cells, which is a concentrated fraction of human neuronal cancer stem cells.
- Promoter 1, 2 and 4 had the next activity intensity, and Promoter 3 had low activity.
- FIG. 10 although the activity of Promoter 5 is slightly observed in the differentiated cancer cell fraction X01GBD cells, the activities of other Promoters 1, 2, 3, and 4 are detected with sensitivity (cut-off). Value) or less.
- the activity of Promoter 5 is almost insignificantly lower than the value in X01GBS cells shown in FIG. 9, and in comparison with the control RSV promoter, CD133 promoter is a fraction enriched in cancer cells. It was revealed that specific activity was observed in the X01GBD cells.
- Example 9 Measurement of CD133 promoter activity in human neuronal cancer stem cell X01GBS (from flow cytometry)
- An adenovirus vector for CD133 promoter activity analysis was constructed in the same manner as in Example 4 and introduced into human neuronal cancer stem cell X01GBS. Two days after the infection, the activity of the CD133 promoter was measured by detecting the expression of LacZ by flow cytometry using the FluoReporter lacZ Flow Cytometry Kit (Molecular Probes, Inc.) according to the manufacturer's attached protocol. Further, CD133 (+) cells were labeled with an anti-CD133 antibody (mouse anti-human CD133 / 2 (293C3) -PE (Miltenyi Biotec)) and measured.
- an anti-CD133 antibody mouse anti-human CD133 / 2 (293C3) -PE (Miltenyi Biotec)
- FIG. 11 shows the correlation between each promoter activity of CD133 in human neuronal cancer stem cell X01GBS and the expression level of CD133 on the cell surface.
- the horizontal axis represents LacZ activity (CD133 promoter activity), and the vertical axis represents anti-CD133 antibody labeled with PE (expression level of CD133 on the cell surface).
- the numerical value (%) shown in FIG. 11 indicates the proportion of cells distributed in the upper right region R7. As shown in FIG. 11, it was revealed that the activity of each promoter of CD133 is correlated with the expression level of CD133.
- FIG. 12 shows a comparison of promoter activity of CD133 in X01GBS cells.
- the horizontal axis represents LacZ activity (CD133 promoter activity)
- the vertical axis represents side scattered light (Side Scatter: SS).
- the numerical value (%) shown in FIG. 12 indicates the proportion of cells distributed in the region R6 surrounded by a square. From these results, among CD133 promoters, promoter 2 and promoter 5 showed particularly high activity.
- each promoter activity of CD133 was confirmed by flow cytometry in X01GBS enriched fraction of human neuronal cancer stem cells and X01GBD fraction enriched in differentiated cancer cells.
- the horizontal axis reflects LacZ activity (CD133 promoter activity)
- the vertical axis reflects the cell morphology and cell internal structures such as nuclei and granules by side scattered light (Side Scatter: SS).
- the numerical value (%) shown in FIG. 13 indicates the promoter activity (rate of LacZ positive) of CD133.
- the proportion of cells exhibiting CD133 promoter activity was higher in the cancer stem cell enriched fraction than in X01GBD.
- Example 11 Construction of a cancer stem cell-specific growth type adenovirus vector
- Construction of a cancer stem cell-specific growth type adenovirus vector As shown in FIG. 14 according to the method described in International Publication No. WO2005 / 012536. Incorporation of five CD133 promoters in front of the E1A region, which is an early gene essential for adenovirus growth, allows a cancer cell-specific growth-regulated adenovirus vector that can specifically kill CD133-expressing tumors ( CD133 reactive m-CRA) was constructed.
- CD133-reactive m-CRA incorporating CD133 promoter 1 is referred to as “hCD133pr1-m-CRA”.
- the names of promoters 2 to 5 are the same.
- CD133-reactive m-CRA incorporating five types of CD133 promoters is collectively referred to as “hCD133pr1-5-m-CRA”.
- Example 2 Measurement of efficiency of introduction of adenovirus vector into human neuronal cancer stem cells
- the culture conditions of neuronal cancer stem cells X01GBS cells were the same as in Example 1 (1).
- the virus infection method was performed in the same manner as in Example 4 (2).
- the vector construction method is described in Chen SH, et al. (1995) PNAS 92 (7): Constructed with reference to the method described in 2577-2581.
- Non-proliferating adenoviral vector (Ad.CA-EGFP) constructed as described above was used to infect human neural cancer stem cells X01GBS at MOI 30. 24 hours after infection, Ad.
- Ad Non-proliferating adenoviral vector constructed as described above was used to infect human neural cancer stem cells X01GBS at MOI 30. 24 hours after infection, Ad.
- the introduction efficiency of CA-EGFP into human neuronal cancer stem cell X01GBS was measured. Specifically, Ad. In CA-EGFP, an EGFP fluorescent protein
- FIG. 15 shows the results of measuring the efficiency of introducing a non-proliferating adenovirus vector into human neuronal cancer stem cells. Since expression of EGFP was confirmed in most X01GBS cells 24 hours after infection, it was confirmed that an adenoviral vector (Ad.CA-EGFP) was efficiently introduced into neuronal cancer stem cells.
- Example 3 Measurement of X01GBS cell killing effect by hCD133pr5-m-CRA
- the culture conditions of neuronal cancer stem cell X01GBS cells were the same as in Example 1 (1).
- the virus infection method was the same as in Example 4 (2).
- HCD133pr5-m-CRA constructed as described above was infected with MOI 3 to human neural cancer stem cells X01GBS.
- Human neuronal cancer stem cells X01GBS into which hCD133pr5-m-CRA had been introduced 1, 2, 3, 4 and 5 days after the infection were observed with a microscope.
- CD133pr5-m-CRA can kill X01GBS cells.
- hCD133pr5-m-CRA causes CPE by X01GBS cells and destroys the cell sphere structure of cancer stem cells. It was confirmed that Further, 5 days after the infection, the cells infected with hCD133pr5-m-CRA were almost dead. This indicates that CD133pr5-mCRA has the ability to kill human neuronal cancer stem cells X01GBS cells.
- Example 4 The culture conditions of neuronal cancer stem cell X01GBS cells are the same as in Example 1 (1).
- the virus infection method is the same as in Example 4 (2).
- RSV-dE1.3 was infected with human neuronal cancer stem cells X01GBS at MOI 1, 3 and 10.
- Non-propagating adenoviral vector (Ad.RSV-dE1.3) is a vector in which the RSV promoter is incorporated into a non-propagating adenoviral vector lacking E1 and E3 regions. Used to evaluate toxicity (different from therapeutic effect). Five days after infection, the number of viable cells was measured using WST-8 cell propagation assay kit (Nakarai).
- Results are shown in FIG. hCD133pr5-m-CRA has been shown to kill X01GBS cells, especially at MOI3 and MOI5.
- Ad CA-EGFP and Ad. Such an effect was not confirmed for RSV-dE1.3.
- Results are shown in FIG.
- the left figure shows hCD133pr5-m-CRA, Ad. CMV-EGFP and Ad. It is the result of measuring the number of viable cells on the third day after infecting RSV-dE1.3 with MOI3 to human neuronal cancer stem cell X01GBS.
- the right figure shows hCD133pr5-m-CRA, Ad. CMV-EGFP and Ad.
- the results of measuring the number of viable cells on day 5 after infection of RSV-dE1.3 with human neuronal cancer stem cells X01GBD differentiated with MOI1 and 3 are shown.
- the vertical axis indicates the ratio (%) of the number of viable cells when compared with the untreated group, and the horizontal axis indicates the virus infection condition (MOI).
- hCD133pr5-m-CRA As shown in FIG. 18, only the hCD133pr5-m-CRA showed a significant cytotoxic effect in the X01GBS enriched fraction of human neuronal stem cells, whereas hCD133pr5-m-CRA is a fraction of the fraction enriched in differentiated cancer cells. Little effect on X01GBD was seen. In other words, hCD133pr5-m-CRA was found to exhibit specific virus growth and cell killing effects in cancer stem cells.
- Example 13 Confirmation of tumorigenic ability of X01GBS
- X01GBS of a fraction enriched with human neuronal cancer stem cells and X01GBD of a fraction enriched with differentiated cancer cells have the same characteristics.
- the transplantation experiment of each fractionated cell to a NOD / SCID immunodeficient mouse was performed, and tumorigenicity was investigated.
- 1 ⁇ 10 6 and 1 ⁇ 10 5 X01GBS cells were transplanted subcutaneously in 4 locations of NOD / SCID immunodeficient mice, and 1 ⁇ 10 6 differentiated X01GBD cells were subcutaneously transplanted in 3 locations of NOD / SCID immunodeficient mice.
- the rate of formation of tumor nodules that could be visually recognized was evaluated.
- mice transplanted with X01GBS cells tumor formation was observed in all mice when any number of cells were transplanted, whereas when X01GBD was transplanted, all cells transplanted with 10 times the amount of cells (1 ⁇ 10 6 ) were transplanted. Tumor formation was not observed in mice. This confirmed the tumor-forming ability of undifferentiated cells X01GBS.
- the skin was incised and the tumor nodules formed subcutaneously were taken out and observed to confirm that the tumor was definitely formed (not a reaction such as inflammation).
- hCD133pr5-m-CRA can be visualized because it proliferates in cancer stem cells and expresses the EGFP gene mounted downstream of the CMV promoter.
- hCD133pr5-m-CRA can be used for, for example, evaluation of therapeutic effects because it enables confirmation of the location of cancer stem cells and measurement of their abundance.
- hCD133pr5-m-CRA was shown to have a therapeutic effect since it has the ability to kill cancer stem cells as well as visualization of cancer stem cells.
- the newly developed growth-regulated adenovirus vector CD133-reactive m-CRA targeting cancer stem cells can be infected and killed by neuronal cancer stem cell X01GBS.
- a treatment visualization effect after virus infection was also obtained.
- the adenovirus vector targeting the cancer stem cells of the present invention cures refractory cancer and promotes recurrence prevention (clinical practical application).
- the viral vector of the present invention can be used for cancer treatment, prevention, metastasis suppression, and diagnosis targeting cancer stem cells, it can be used in the field of therapeutic agents and diagnostic agents.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
Description
(1) 所望の遺伝子に作動可能に連結させたCD133プロモーターを有する、癌幹細胞特異的に当該所望の遺伝子を発現可能なウイルスベクター。
(2) 前記所望の遺伝子がウイルスの増殖に必須のタンパク質をコードする遺伝子であって、癌幹細胞特異的に増殖可能である(1)に記載のウイルスベクター。
(3) 腫瘍溶解性である(2)に記載のウイルスベクター。
(4) アデノウイルス、単純ヘルペスウイルス、ミキソーマウイルス、レオウイルス、ベジキュラー・ストマタイティスウイルス、ニューキャッスル病ウイルス、ワクシニアウイルス、RSウイルス、センダイウイルス、麻疹ウイルス、コクサッキーウイルス、又はセネカ・ヴァレイ・ウイルスである(2)又は(3)に記載のウイルスベクター。
(5) アデノウイルスである(2)又は(3)に記載のウイルスベクター。
(6) 前記所望の遺伝子がアデノウイルスのE1A又はE1B遺伝子である、(5)に記載のアデノウイルスベクター。
(7) E1Aが、Rb結合領域が欠損したE1A(E1AΔ24)である、又は、E1Bが、p53結合領域が欠損したE1B(E1BΔ55)である、(6)に記載のアデノウイルスベクター。
(8) 更に、標識遺伝子、又は細胞毒性遺伝子を備える(2)~(7)のいずれか1項に記載のアデノウイルスベクター。
(9) 更に、外来性の癌特異的プロモーターを備える(2)~(8)のいずれか1項に記載のウイルスベクター。
(10) 以下の(a)~(c)から選択される1のアデノウイルスベクターである、(6)又は(7)に記載のアデノウイルスベクター:
(a)以下の転写ユニットを有するアデノウイルスべクター:
(a1)CD133プロモーター及びその下流に作動可能に連結されたE1A遺伝子又はE1AΔ24遺伝子からなるCD133転写ユニット
(a2)真核細胞プロモーター、癌特異的プロモーター又はCD133プロモーター及びその下流に作動可能に連結されたE1B遺伝子又はE1BΔ55K遺伝子からなる転写ユニット、あるいは、癌特異的プロモーターの下流に作動可能に連結されたE1BΔ19K遺伝子からなる転写ユニット
(a3)任意に、真核細胞プロモーター、癌特異的プロモーター又はCD133プロモーター及びその下流に作動可能に連結された標識遺伝子又は細胞毒性遺伝子からなる追加転写ユニット;
(b)以下の転写ユニットを有するアデノウイルスべクター:
(b1)真核細胞プロモーター、癌特異的プロモーター又はCD133プロモーター及びその下流に作動可能に連結されたE1A遺伝子又はE1AΔ24遺伝子からなる転写ユニット、
(b2)CD133プロモーター及びその下流に作動可能に連結されたE1B遺伝子又はE1BΔ55K遺伝子からなるCD133転写ユニット、
(b3)任意に、真核細胞プロモーター、癌特異的プロモーター又はCD133プロモーター及びその下流に作動可能に連結された標識遺伝子又は細胞毒性遺伝子からなる追加転写ユニット;
(c)以下の転写ユニットを有するアデノウイルスべクター:
(c1)真核細胞プロモーター、癌特異的プロモーター又はCD133プロモーター及びその下流に作動可能に連結されたE1A遺伝子又はE1AΔ24遺伝子からなる転写ユニット、
(c2)真核細胞プロモーター、癌特異的プロモーター又はCD133プロモーター及びその下流に作動可能に連結されたE1B遺伝子又はE1BΔ55K遺伝子からなる転写ユニット、
(c3)CD133プロモーター及びその下流に作動可能に連結された標識遺伝子又は細胞毒性遺伝子からなるCD133転写ユニット。
(11) 前記所望の遺伝子が標識遺伝子である(1)に記載のウイルスベクター。
(12) 更に、外来性の癌特異的プロモーターを備える(11)に記載のウイルスベクター。
(13) 更に、細胞毒性遺伝子を備える(11)又は(12)に記載のウイルスベクター。
(14) 前記所望の遺伝子が、細胞毒性遺伝子である請求項1に記載のウイルスベクター。
(15) 更に、外来性の癌特異的プロモーターを備える(14)に記載のウイルスベクター。
(16) 更に、標識遺伝子を備える(14)又は(15)のいずれか1項に記載のアデノウイルスベクター。
(17) 腫瘍溶解性ウイルスである(11)~(16)のいずれか1項に記載のウイルスベクター。
(18) アデノウイルス、単純ヘルペスウイルス、ミキソーマウイルス、レオウイルス、ベジキュラー・ストマタイティスウイルス、ニューキャッスル病ウイルス、ワクシニアウイルス、RSウイルス、センダイウイルス、麻疹ウイルス、コクサッキーウイルス、又はセネカ・ヴァレイ・ウイルスである(11)~(17)のいずれか1項に記載のウイルスベクター。
(19) CD133プロモーターが、以下の(i)~(iv)から選択されるいずれか1項に記載の核酸分子である、(1)~(18)のいずれか1項に記載のウイルスベクター:
(i)配列番号1~5のいずれか1つの配列番号に記載のヌクレオチド配列を有する核酸分子、
(ii)配列番号1~5のいずれかの配列番号に記載のヌクレオチド配列と85%の相同性を有するヌクレオチド配列を有する核酸分子、
(iii)配列番号1~5のいずれかの配列番号に記載のヌクレオチド配列を有する核酸分子又はそれと相補的な配列を有する核酸分子とストリンジェントな条件下でハイブリダイズする核酸分子、
(iv)配列番号1~5のいずれかの配列番号に記載のヌクレオチド配列の一部の核酸が置換、欠失し、又は、配列番号1~5のいずれかの配列番号に記載のヌクレオチド配列に追加の核酸が付加、挿入された核酸分子。
(20) (1)~(19)のいずれか1項に記載のウイルスベクターを含有する癌の治療薬、転移抑制剤、若しくは予防薬又は診断薬。
(21) (1)~(19)のいずれか1項に記載のウイルスベクターを含有する癌幹細胞の標識剤。
(22) 更に、同時に、連続的に又は時間をおいて別々に投与される以下の(i)~(ii)から選択される1以上の薬剤を含有する(20)に記載の治療薬若しくは予防薬又は診断薬:
(i)抗ウイルス作用を低下させる薬剤、
(ii)抗癌剤。
(23) (1)~(19)のいずれか1項に記載のウイルスベクターをそれを必要とする患者に投与するステップを備える癌幹細胞の標識方法。
(24) (1)~(19)のいずれか1項に記載のウイルスベクターをそれを必要とする患者に投与するステップを備える癌の診断方法。
(25) ウイルスベクターが標識遺伝子を有する、(23)又は(24)に記載の方法。
(26) (1)~(20)のいずれか1項に記載のウイルスベクターをそれを必要とする患者に投与するステップを備える癌の予防方法、転移抑制方法、又は治療方法。
(27) 更に、前記ウイルスベクターを患者の癌幹細胞に感染させるステップを備える(26)に記載の予防方法、転移抑制方法、又は治療方法。
(28) ウイルスベクターが細胞毒性遺伝子を有する、(26)又は(27)に記載の方法。
(29) 前記所望の遺伝子がウイルスの増殖に必須のタンパク質をコードする遺伝子であって、前記ウイルスベクターが癌幹細胞特異的に増殖可能である(23)~(28)のいずれか1項に記載の方法。
(a)以下の転写ユニットを有するアデノウイルスべクター:
(a1)CD133プロモーター及びその下流に作動可能に連結されたE1A遺伝子又はE1AΔ24遺伝子からなるCD133転写ユニット
(a2)真核細胞プロモーター、癌特異的プロモーター又はCD133プロモーター及びその下流に作動可能に連結されたE1B遺伝子又はE1BΔ55K遺伝子からなる転写ユニット、あるいは、癌特異的プロモーターの下流に作動可能に連結されたE1BΔ19K遺伝子からなる転写ユニット
(a3)任意に、真核細胞プロモーター、癌特異的プロモーター又はCD133プロモーター及びその下流に作動可能に連結された標識遺伝子又は細胞毒性遺伝子からなる追加転写ユニット;
(b)以下の転写ユニットを有するアデノウイルスべクター:
(b1)真核細胞プロモーター、癌特異的プロモーター又はCD133プロモーター及びその下流に作動可能に連結されたE1A遺伝子又はE1AΔ24遺伝子からなる転写ユニット、
(b2)CD133プロモーター及びその下流に作動可能に連結されたE1B遺伝子又はE1BΔ55K遺伝子からなるCD133転写ユニット、
(b3)任意に、真核細胞プロモーター、癌特異的プロモーター又はCD133プロモーター及びその下流に作動可能に連結された標識遺伝子又は細胞毒性遺伝子からなる追加転写ユニット;
(c)以下の転写ユニットを有するアデノウイルスべクター:
(c1)真核細胞プロモーター、癌特異的プロモーター又はCD133プロモーター及びその下流に作動可能に連結されたE1A遺伝子又はE1AΔ24遺伝子からなる転写ユニット、
(c2)真核細胞プロモーター、癌特異的プロモーター又はCD133プロモーター及びその下流に作動可能に連結されたE1B遺伝子又はE1BΔ55K遺伝子からなる転写ユニット、
(c3)CD133プロモーター及びその下流に作動可能に連結された標識遺伝子又は細胞毒性遺伝子からなるCD133転写ユニット。
本明細書において「癌幹細胞」とは、腫瘍内の細胞であって自己複製能力及び腫瘍を含む癌細胞の異種系列をもたらす能力を有する細胞(Clarke MFら、Cancer Res.(2006)66:9339-9344)を意味する。即ち、癌幹細胞は、自己と同一の性質を有する娘細胞を産生する能力と癌組織を形成する細胞(特に悪性腫瘍)への分化能の両方を有する。但し、これは幹細胞様(Stem-like)の性質をある程度持っているという意味であり、正常の幹細胞のような厳密な幹細胞の性格を持つ必要はなく(その条件に限定されるものではなく)、むしろ癌の悪性化の主原因という点が重要である。少数の癌幹細胞が、分化により癌組織を形成する多数の癌細胞となることから、Tumor-Initiating Cell又はCancer Initiating Cell(癌始原細胞あるいは腫瘍又は癌の創始細胞)と呼ばれることもある。本発明における癌幹細胞は、これらの癌始原細胞あるいは腫瘍又は癌の創始細胞をも含むものである(Neuzil J,et al.Biochem Biophys Res Comm.355;855-859,2007)。例えば、癌幹細胞は、数個~数万個(好ましくは数十個~数千個)の細胞を免疫不全マウスに移植した場合に癌を形成することができる細胞であってもよい。また、本明細書における癌幹細胞がこれに限定されるものではないが、固形癌における癌幹細胞は、CD24、CD44、CD90、CD133、ABCB5等のマーカーを発現することが知られている。例えば、本発明の癌幹細胞は、脳腫瘍、グリア芽腫、頭頚部癌、胃癌、肺癌、乳癌、子宮癌、卵巣癌、肝癌、気管支癌、上咽頭癌、咽頭癌、食道癌、膀胱がん、膵臓癌、前立腺癌、大腸癌、骨肉腫、皮膚癌、メラノーマ、甲状腺癌、副甲状腺癌、尿管癌、子宮頸癌等の固形癌及び肉腫、並びに造血器や血液の悪性腫瘍(例えば、急性リンパ性白血病等の白血病、悪性リンパ腫)の癌幹細胞を含む。好ましくは、癌幹細胞は脳腫瘍幹細胞又はグリア芽腫幹細胞である。
本発明のウイルスベクターは、当業者に知られたウイルスベクター作製方法を適宜採用して作製することができる。例えば、ウイルスベクターは、ほぼ完全なウイルスゲノムのコピーを有するウイルスバックボーンプラスミドとCD133転写ユニットを有するシャトルベクタープラスミドを遺伝子組み換えの技術を利用して組替えることにより作製することができる。遺伝子組み換えは、相同的組換、制限酵素サイト(好ましくは、l-CeuI及びPl-SceI等の特殊制限酵素サイト)を利用した組換、又は、リコンビネーション反応(例えば、Cre-LoxP)を利用した組換により行うこともできる。
本発明は、本発明のウイルスベクターのうち、ウイルスの増殖に必須のタンパク質をコードする遺伝子に作動可能に連結させたCD133プロモーターを有する、癌幹細胞特異的に増殖可能なウイルスベクター及び/又は細胞毒性遺伝子を有するウイルスベクター(以下、総称して「治療用ウイルスベクター」という)を、それを必要とする患者に投与することを含む、癌の治療方法、予防方法、転移抑制方法に関する。本発明の治療用ウイルスベクターは、癌細胞を生み出す元である癌幹細胞に傷害を与えることができるため、そのようなウイルスベクターを癌患者又は癌になることが予想される患者に投与することにより癌を治療し又は予防し、あるいは癌の転移を抑制することができる。よって、本発明の一例は、治療用ウイルスベクターを、それを必要とする患者に投与し、それにより該患者の癌幹細胞内において該ウイルスベクターを増殖させ、又は細胞毒性遺伝子を発現させることを含む、癌の治療方法、予防方法、又は転移抑制方法である。
本発明は、本発明のウイルスベクターのうち、標識遺伝子を有するウイルスベクター(以下、「標識用ウイルスベクター」という)を、対象患者に投与することを含む、癌の診断方法、又は癌幹細胞の標識方法に関する。本発明の標識用ウイルスベクターは、癌幹細胞で特異的に標識遺伝子を発現することができるため、そのようなウイルスベクターを癌患者又は癌になることが予想される患者に投与することにより癌幹細胞を同定又は識別することができる。癌幹細胞は癌細胞内に数~十数%存在することが知られていることから、癌幹細胞の存在を指標に癌を診断することができる。また、癌の切除等の場面においては癌の増殖の根源である癌幹細胞の除去が重要であると考えられており、癌幹細胞を特異的に標識して可視化することにより、癌幹細胞の確実な切除を助けて手術の成功率を高め、手術後の患者の予後を改善することができる。具体的には、本発明は、標識用ウイルスベクターを対象患者に投与し、標識遺伝子の発現産物を検出することを含む、癌の診断方法、又は癌幹細胞の標識方法に関する。標識遺伝子の発現産物の検出は、使用する標識遺伝子の種類と使用目的により適宜選択することができ、例えば、外科手術中に色素又は蛍光色素を目視で確認してもよいし、画像診断により検出してもよい。また、癌の診断又は癌幹細胞の標識は、癌幹細胞を可視化することにより行ってもよいし、視覚以外の手段で検知可能な手法により行ってもよい。例えば、本発明の癌の診断方法、又は癌幹細胞の標識方法は、標識用ウイルスベクターを、対象患者に投与することを含む、癌幹細胞の可視化方法であってもよい。
本発明のウイルスベクターを有効成分として包含する医薬組成物(癌の治療薬、予防薬、転移抑制剤及び診断薬、並びに癌幹細胞の標識剤、及び傷害剤を含む)は、有効成分に加えて1以上の薬学的に許容可能な担体を含む組成物であってもよい。医薬組成物が溶液製剤の場合、このような薬学的に許容可能な担体は、滅菌可能でヒトに投与可能な一般的に知られている担体であればよく、限定されない例として、生理食塩水、滅菌水、リンガー液、緩衝生理食塩水、アルブミン注射液、デキストロース溶液、マルトデキストリン溶液、グリセロール、エタノール、及びこれらの組み合わせを挙げることができる。また、必要に応じて、医薬組成物は、更に抗酸化剤、緩衝剤及び静菌剤を含有していてもよい。また、医薬組成物は用事調整可能な注射用製剤としてもよい。この場合、医薬組成物(医薬組成物キット)は、希釈剤、分散剤、界面活性剤、結合剤、及び潤滑剤を含んでいてもよい。
(1)細胞
ヒト神経癌幹細胞として、Soeda A, et al. J Biol Chem 2008;283;10958-66に記載されたヒト神経癌幹細胞(human glioblastoma stem cells)を使用した。X01GBS細胞は、X01GB細胞の癌幹細胞分画であり、未分化条件の培地とSphere培養法で癌幹細胞分画を「濃縮」した細胞群である。よって、以下、特に明記が無い限りにおいて、ヒト神経癌幹細胞X01GBSとはSoeda A, et al. J Biol Chem 2008;283;10958-66に記載されたヒト神経癌幹細胞(human glioblastoma stem cells)(又はX01GB-CSC)を意味するものとする。培養条件:神経癌幹細胞X01GBSをB-27(Invitrogen),recombinante human FGF-2(20 ng/ml;R&D Systems, Minneapolis, MN)とrecombinant human EGF (20 ng/ml;R&D Systems)添加した10%FBSとpenicillin G, stretomycinsulfateを含有するDulbecco‘s modified Eagle’s medium/F-12(D6421,Sigma)培地で5%CO2、37℃で培養した。以下の実験に特に説明しなければ同じ条件でX01GBS細胞培養を行った。
また、X01GBD細胞は、このヒト神経癌幹細胞(神経膠芽腫由来の癌幹細胞;human glioblastom stem cell)が濃縮された細胞群であるX01GBS細胞から、以下の方法で樹立された、「分化したヒト神経癌細胞」(分化した神経膠芽腫(human glioblastoma))が濃縮した細胞群として作製した。X01GBD細胞は、Inagaki A, et al. Biochem Biopys Res Commun 2007;361;586-592に記載された樹立法及び分化した状態での維持培養法に従って樹立、維持された。つまり、X01GBS細胞を10%のウシ胎児血清Fetal bovine serumを加えてFGF-2を除いたDulbecco’s modified Eagle’s medium/F-12培地中、通常の接着可能な培養ディッシュで接着単層培養し、これを長期(50継代以上繰り返し)培養し維持することで、癌幹細胞分画が劇的に減少し、ほとんどが分化した癌細胞分画に置き換わった細胞群であるX01GBD細胞を得た。X01GBD細胞の特性は、Inagaki A, et al. Biochem Biopys Res Commun 2007;361;586-592に記載された通りであった。
つまり同一患者の同一組織であるヒト脳神経悪性腫瘍から、悪性度の強い未分化性が高い癌幹細胞分画のX01GBS細胞群と、分化した悪性度の低いX01GBD細胞群が樹立された。
第一抗体として、以下の抗体を使用した:
抗ネスチン(nestin)ウサギポリクローナル抗体(Chemicon,Temecula,CA)
抗ビメンチン(Vimentin)ウサギポリクローナル抗体(Ab45939、Abcam,UK)
抗CD133ウサギポリクローナル抗体(Ab19898,Abcam,UK)
抗βIIIチューブリン(tubulin)(Tuj1)マウスモノクローナル抗体TU20(Ab7751、Abcam,UK)
第二抗体として、波長488nmの緑色蛍光色素と結合した以下の抗体を使用した:
Alexa fluorophore-conjugated 488(mouse/rabbit,Molecular Probes,Invitrogen)
ヒト神経癌幹細胞X01GBSの細胞塊(spheres)を、0.1%ゼラチンコートしたカバーガラス上に播種し、B-27(Invitrogen),recombinante human FGF-2(20 ng/ml;R&D Systems, Minneapolis, MN)とrecombinant human EGF (20 ng/ml;R&D Systems)添加した10%FBSとpenicillin G, stretomycinsulfateを含有するDulbecco‘s modified Eagle’s medium/F-12(D6421,Sigma)培地に5%CO2、37℃で4時間培養した。その後、細胞を1×PBSで洗浄し、400μLの4%PFA/PBSで、室温に15分間固定した。固定後の細胞を1×PBSで洗浄後、第一抗体を細胞に添加し室温に1時間で反応をさせた。反応後1×PBSで洗浄し、第二抗体を上述の希釈率となるように添加し、室温で30分間反応後、PBSで洗浄した。
室温で細胞免疫染色を行った細胞にMounting Medium with DAPI(H-1500, Vector laboratories, Inc., USA)1滴を添加すると、細胞核をすぐ染色された。
(1)細胞
ヒト神経癌幹細胞X01GBS、陽性コントロールとして大腸癌細胞(Caco-2)及びヒトiPS細胞(201B7,理化学研究所より購入)を使用した。
(2)抗体
第一抗体として、抗CD133ウサギポリクローナル抗体(Ab19898,Abcam,UK)(希釈率1:1000)を使用し、第二抗体として、ヤギ抗ウサギポリクローナル抗体IgG/HRP(Dako,Cytomation)(希釈率1:2000)を使用した。
(3)ウエスタンブロッティング
培養した細胞を含む10cmディッシュの培養液を捨てて、PBSで洗浄後、たんぱく質保護剤0.5mM PMSFとProtease inhibitor cocktail(直前に加える)含む可溶化RIPAバッファー(0.5% NP40,0.1% SDS,0.5% Sodium deoxycholate,150mM NaClと50mM Tris(pH7.5))を1mL加え細胞を溶解させた。細胞可溶化溶液と等量の2×サンプルバッファー(4% SDS、20%グリセロール、0.06% β-メルカプトエタノール、100mM Tris(pH6.8)、0.1% ブロモフェノブルー)を加え、95℃で5分煮沸した。10%ポリアクリルアミドゲル(196-12921、Wako)にサンプルを20μgアプライして、電気泳動を行った。メンブレンを転写装置から取り除き、ブロッキングバッファー(5% non-fat dry milk、10mM Tris(pH7.5)、100mM NaCl、0.1% Tween20)に浸して、室温で1時間振とうしてブロッキングした。ブロッキングバッファーを除去後、ブロッキングバッファーで1:1000に希釈した一次抗体反応液を加え、メンブレンを室温で1時間振とうで反応させた。その後、一次抗体液を除去し、ウォッシュバッファー(10mM Tris(pH7.5)、100mM NaCl、0.1% Tween20)を加えて、メンブレンを振とうしながら、室温で15分間、3回洗浄した。ウォッシュバッファーを除去し、2000倍に希釈した二次抗体反応液を加え、メンブレンを振とうしながら、室温で1時間反応させた。二次抗体反応液を除去して、ウォッシュバッファーを添加し、メンブレンを振とうしながら、室温で15分間3回洗浄した。ウォッシュバッファーを除去後、0.125mL/cm2の化学発光反応液Chemi-Lumi One(05027-20,Wako)をメンブレンに加えて1分間反応させてから、露光してタンパク質の発現を検出した。
(1)FCM(1回目)
FCM解析は使用する抗体の製造者Miltenyi Biotec社の添付のプロトコールに従って行った。ヒト神経癌幹細胞X01GBSを使用際にCD133(+)細胞含量を確認した。
図中、楕円で囲んだ範囲に含まれる細胞を全細胞として解析を行った。
(2)FCM(2回目)
一回目と同様にFACSを行った。抗体として、マウス抗ヒトCD133/2(293C3)-PE、及び、マウスIgG-PE(共にMiltenyi Biotec社)を使用した。BD FACSAriaTM II Flow Cytometerを用いて検出した。
ヒト神経癌幹細胞の濃縮分画であるX01GBS細胞と、それから分化した癌細胞を濃縮した分画のX01GBD細胞において、CD133発現の陽性細胞株であるCaco-2細胞(大腸がん)とCD133陰性の細胞である正常細胞のWI-38細胞(線維芽細胞)とともに、同時にフローサイトメトリを行った。
ヒト神経癌幹細胞の濃縮分画であるX01GBS細胞、それから分化した癌細胞を濃縮した分画のX01GBD細胞、及び正常細胞であるWI-38細胞におけるCD133のmRNAの発現レベルを、RT-PCR法後の電気泳動、ならびに定量的RT-PCR法で調べた。ハウスキーピング遺伝子であるHPRTを、RT-PCRのコントロール遺伝子として用いた。
さらにヒト神経癌幹細胞の濃縮分画であるX01GBS細胞をセルソーターにてCD133発現の陽性細胞と陰性細胞に分けて分取し、それぞれの分画において、同様にCD133 mRNA発現レベルを、RT-PCRならびに定量的RT-PCR法で調べた。
(1)CD133プロモーター活性解析用のアデノウイルスベクターの構築
ヒトCD133については、5種類のプロモーターが知られており、それぞれ、プロモーター1(pr1;配列番号1)、プロモーター2(pr2;配列番号2)、プロモーター3(pr3;配列番号3)、プロモーター4(pr4;配列番号4)、及びプロモーター5(pr5;配列番号5)と呼ばれている(Sergey V.Shmelkovら,BLOOD,15 MARCH 2004,Vol.103,No.6)。ヒト神経癌幹細胞X01GBSにおける各プロモーター活性を測定するため、図7に示すように、5つのヒトCD133プロモーターの下流にLacZを連結して、E1領域欠損する非増殖型アデノウイルスベクターに組み込み、レポータアッセイ用アデノウイルスベクターを構築した。以下、pr1の下流にLacZを連結したものをアデノウイルスベクターに組み込んだベクターを「Ad.hCD133pr1-LacZ」といい、同様にpr2~pr5の下流にLacZを連結したものをアデノウイルスベクターのΔE1に組み込んだベクターを、それぞれ「Ad.hCD133pr2-LacZ」、「Ad.hCD133pr3-LacZ」、「Ad.hCD133pr4-LacZ」、「Ad.hCD133pr5-LacZ」という。また、これらのベクターを総称して「Ad.hCD133pr1-5-LacZ」という。
ベクターの構築方法はChen SH, et al.(1995)PNAS 92 (7):2577-2581記載の方法に参考して構築した。
(2)ヒト神経癌幹細胞X01GBSにおけるCD133プロモーター活性測定
神経癌幹細胞X01GBS細胞の培養条件が実施例1の(1)と同じ。ウイルスの感染方法は感染する予定の細胞を1.5mlチューブに集めて、一回遠心してから、上清を除いて、ウイルス入りの培養液で細胞pptに加え、1時間、37℃でウイルス感染を行った。感染途中、15分毎にtappingかpipettingを行って、ウイルスと細胞の接触回数を増やし感染効率を上げるようにした。
上述の通り構築したレポータアッセイ用アデノウイルスベクター(Ad.hCD133pr1-5-LacZ)を細胞1個に対するウイルスの数MOI (multiplicity of infrction)数で感染を行った。MOI 30でヒト神経癌幹細胞X01GBSに感染させた。感染二日後にBeta-galactosidase enzyme assay system(Promega,USA)を用いて、製造者添付のプロトコールに従って、ヒトCD133の各プロモーターの活性を測定した。
さらに、CD133プロモーターの特性をより詳細に調べるため、ヒト神経癌幹細胞の濃縮分画であるX01GBS細胞と、それから分化した癌細胞を濃縮した分画のX01GBD細胞において、同様のCD133プロモーターアッセイの実験を行った。各グループはN=3で行った。陽性コントロールとしてRSVプロモーターを、陰性コントロールとしてはプロモーターの挿入されていないアデノウイルス(ΔPr)、ならびにアデノウイルスを加えていない細胞(NC)を用いた。活性の感度を上げて詳細に比較できるように、アデノウイルスの感染方法やβ-gala activityの活性測定の感度が上昇できるような各実験ステップでの小さな工夫を除いては、基本的な実験方法は実施例7と同一であった。
CD133プロモーター活性解析用のアデノウイルスベクターは、実施例4と同様の方法により構築し、ヒト神経癌幹細胞X01GBSに導入した。感染二日後にフローサイトメトリにより、FluoReporter lacZ Flow Cytometry Kit(Molecular Probes, Inc.)を用いて、製造者添付のプロトコールに従いLacZの発現を検出することで、CD133プロモーターの活性を測定した。また、抗CD133抗体(マウス抗ヒトCD133/2(293C3)-PE(Miltenyi Biotec社))を用いてCD133(+)細胞を標識して、測定した。
さらにヒト神経癌幹細胞を濃縮分画のX01GBSと、分化した癌細胞を濃縮した分画のX01GBDにおいて、CD133の各プロモーター活性をフローサイトメトリで確認した。
(1)癌幹細胞特異的増殖型アデノウイルスベクターの構築
国際公開第WO2005/012536号パンフレット記載の方法に準じて、図14に示すように5つのCD133プロモーターをアデノウイルスの増殖に必須な初期遺伝子であるE1A領域の前に組み込むことにより、CD133発現腫瘍に特異的に殺傷することのできる癌幹細胞特異的な増殖制御型アデノウイルスベクター(CD133反応性m-CRA)を構築した。以下、CD133プロモーター1を組み込んだCD133反応性m-CRAを「hCD133pr1-m-CRA」という。プロモーター2~5についても同様に命名する。また、5種類のCD133プロモーターを組み込んだCD133反応性m-CRAを総称して「hCD133pr1-5-m-CRA」という。
神経癌幹細胞X01GBS細胞の培養条件は実施例1の(1)と同じとした。またウイルスの感染方法は実施例4の(2)と同様に行った。
ベクターの構築方法はChen SH, et al.(1995)PNAS 92 (7):2577-2581記載の方法に参考して構築した。
上述の通り構築した非増殖型アデノウイルスベクター(Ad.CA-EGFP)を用いて、MOI 30でヒト神経癌幹細胞X01GBSに感染させた。感染から24時間後にAd.CA-EGFPのヒト神経癌幹細胞X01GBSへの導入効率を測定した。具体的には、Ad.CA-EGFPは、CAプロモーターの下流にEGFP蛍光たんぱく質遺伝子が導入している。ことから、Ad.CA-EGFPの感染によりEGFPの発現が確認できた。
神経癌幹細胞X01GBS細胞の培養条件が実施例1の(1)と同じとした。ウイルスの感染方法は実施例4の(2)と同様に行った。
上述の通り構築したhCD133pr5-m-CRAをMOI 3でヒト神経癌幹細胞X01GBSに感染させた。感染から1,2,3,4及び5日後にhCD133pr5-m-CRAを導入したヒト神経癌幹細胞X01GBSを顕微鏡で観察した。
神経癌幹細胞X01GBS細胞の培養条件が実施例1の(1)と同じ。ウイルスの感染方法は実施例4の(2)と同じ。
上述の通り構築したhCD133pr5-m-CRA、並びにネガティブコントロールとして、Ad.CA-EGFP及びAd.RSV-dE1.3をMOI 1、3、及び10でヒト神経癌幹細胞X01GBSに感染させた。非増殖型アデノウイルスベクター(Ad.RSV-dE1.3)はRSVプロモーターをE1とE3領域欠損する非増殖型アデノウイルスベクターに組み込んだベクターで、アデノウイルスの感染実験にウイルスの感染によるウイルス自身の毒性(治療効果と違い)を評価するため使う。感染から5日後にWST-8 cell proliferation assay kit(Nakarai社)を用いて、生存細胞数を測定した。
さらにhCD133pr-m-CRAの殺傷治療効果が、癌幹細胞特異的であることを示すため、同様の実験をヒト神経癌幹細胞を濃縮分画のX01GBSだけでなく、分化した癌細胞を濃縮した分画のX01GBDでも行い、比較した。
またヒト神経癌幹細胞を濃縮分画のX01GBSと、分化した癌細胞を濃縮した分画のX01GBDが、その通りの特性を持つことを確証するため、NOD/SCID免疫不全マウスへのそれぞれの分画細胞の移植実験を行い、腫瘍形成能を調べた。1×106と1×105のX01GBS細胞をNOD/SCID免疫不全マウスの4ヶ所に、1×106の分化X01GBD細胞をNOD/SCID免疫不全マウスの3ヶ所に皮下移植した。その10週間後、肉眼的に認識できる腫瘍結節の形成の割合を評価した。
Claims (27)
- 所望の遺伝子に作動可能に連結させたCD133プロモーターを有する、癌幹細胞特異的に当該所望の遺伝子を発現可能なウイルスベクター。
- 前記所望の遺伝子がウイルスの増殖に必須のタンパク質をコードする遺伝子であって、癌幹細胞特異的に増殖可能である、請求項1に記載のウイルスベクター。
- 腫瘍溶解性である、請求項2に記載のウイルスベクター。
- アデノウイルス、単純ヘルペスウイルス、ミキソーマウイルス、レオウイルス、ベジキュラー・ストマタイティスウイルス、ニューキャッスル病ウイルス、ワクシニアウイルス、RSウイルス、センダイウイルス、麻疹ウイルス、コクサッキーウイルス、又はセネカ・ヴァレイ・ウイルスである、請求項2又は請求項3に記載のウイルスベクター。
- アデノウイルスである、請求項2又は請求項3に記載のウイルスベクター。
- 前記所望の遺伝子がアデノウイルスのE1A又はE1B遺伝子である、請求項5に記載のアデノウイルスベクター。
- E1Aが、Rb結合領域が欠損したE1A(E1AΔ24)である、又は、E1Bが、p53結合領域が欠損したE1B(E1BΔ55K)である、請求項6に記載のアデノウイルスベクター。
- 更に、標識遺伝子、又は細胞毒性遺伝子を備える、請求項2~請求項7のいずれか1項に記載のアデノウイルスベクター。
- 更に、外来性の癌特異的プロモーターを備える、請求項2~請求項8のいずれか1項に記載のウイルスベクター。
- 以下の(a)~(c)から選択される1のアデノウイルスベクターである、請求項6又は請求項7に記載のアデノウイルスベクター:
(a)以下の転写ユニットを有するアデノウイルスべクター:
(a1)CD133プロモーター及びその下流に作動可能に連結されたE1A遺伝子又はE1AΔ24遺伝子からなるCD133転写ユニット
(a2)真核細胞プロモーター、癌特異的プロモーター又はCD133プロモーター及びその下流に作動可能に連結されたE1B遺伝子又はE1BΔ55K遺伝子からなる転写ユニット、あるいは、癌特異的プロモーターの下流に作動可能に連結されたE1BΔ19K遺伝子からなる転写ユニット
(a3)任意に、真核細胞プロモーター、癌特異的プロモーター又はCD133プロモーター及びその下流に作動可能に連結された標識遺伝子又は細胞毒性遺伝子からなる追加転写ユニット;
(b)以下の転写ユニットを有するアデノウイルスべクター:
(b1)真核細胞プロモーター、癌特異的プロモーター又はCD133プロモーター及びその下流に作動可能に連結されたE1A遺伝子又はE1AΔ24遺伝子からなる転写ユニット、
(b2)CD133プロモーター及びその下流に作動可能に連結されたE1B遺伝子又はE1BΔ55K遺伝子からなるCD133転写ユニット、
(b3)任意に、真核細胞プロモーター、癌特異的プロモーター又はCD133プロモーター及びその下流に作動可能に連結された標識遺伝子又は細胞毒性遺伝子からなる追加転写ユニット;
(c)以下の転写ユニットを有するアデノウイルスべクター:
(c1)真核細胞プロモーター、癌特異的プロモーター又はCD133プロモーター及びその下流に作動可能に連結されたE1A遺伝子又はE1AΔ24遺伝子からなる転写ユニット、
(c2)真核細胞プロモーター、癌特異的プロモーター又はCD133プロモーター及びその下流に作動可能に連結されたE1B遺伝子又はE1BΔ55K遺伝子からなる転写ユニット、
(c3)CD133プロモーター及びその下流に作動可能に連結された標識遺伝子又は細胞毒性遺伝子からなるCD133転写ユニット。 - 前記所望の遺伝子が標識遺伝子である、請求項1に記載のウイルスベクター。
- 更に、外来性の癌特異的プロモーターを備える、請求項11に記載のウイルスベクター。
- 更に、細胞毒性遺伝子を備える、請求項11又は請求項12に記載のウイルスベクター。
- 前記所望の遺伝子が、細胞毒性遺伝子である請求項1に記載のウイルスベクター。
- 更に、外来性の癌特異的プロモーターを備える、請求項14に記載のウイルスベクター。
- 更に、標識遺伝子を備える、請求項14又は請求項15のいずれか1項に記載のアデノウイルスベクター。
- 腫瘍溶解性ウイルスである、請求項11~請求項16のいずれか1項に記載のウイルスベクター。
- アデノウイルス、単純ヘルペスウイルス、ミキソーマウイルス、レオウイルス、ベジキュラー・ストマタイティスウイルス、ニューキャッスル病ウイルス、ワクシニアウイルス、RSウイルス、センダイウイルス、麻疹ウイルス、コクサッキーウイルス、又はセネカ・ヴァレイ・ウイルスである、請求項11~請求項17のいずれか1項に記載のウイルスベクター。
- CD133プロモーターが、以下の(i)~(iv)から選択されるいずれか1項に記載の核酸分子である、請求項1~請求項18のいずれか1項に記載のウイルスベクター:
(i)配列番号1~5のいずれか1つの配列番号に記載のヌクレオチド配列を有する核酸分子、
(ii)配列番号1~5のいずれかの配列番号に記載のヌクレオチド配列と85%の相同性を有するヌクレオチド配列を有する核酸分子、
(iii)配列番号1~5のいずれかの配列番号に記載のヌクレオチド配列を有する核酸分子又はそれと相補的な配列を有する核酸分子とストリンジェントな条件下でハイブリダイズする核酸分子、
(iv)配列番号1~5のいずれかの配列番号に記載のヌクレオチド配列の一部の核酸が置換、欠失し、又は、配列番号1~5のいずれかの配列番号に記載のヌクレオチド配列に追加の核酸が付加、挿入された核酸分子。 - CD133プロモーターが、CD133のプロモータ5である、請求項1~請求項19のいずれか1項に記載のウイルスベクター。
- 請求項1~請求項20のいずれか1項に記載のウイルスベクターを含有する癌の治療薬、転移抑制剤、若しくは予防薬又は診断薬。
- 請求項1~請求項20のいずれか1項に記載のウイルスベクターを含有する癌幹細胞の標識剤。
- 更に、同時に、連続的に又は時間をおいて別々に投与される以下の(i)~(ii)から選択される1以上の薬剤を含有する、請求項21に記載の治療薬若しくは予防薬又は診断薬:
(i)抗ウイルス作用を低下させる薬剤、
(ii)抗癌剤。 - 請求項1~請求項20のいずれか1項に記載のウイルスベクターをそれを必要とする患者に投与するステップを備える癌幹細胞の標識方法。
- 請求項1~請求項20のいずれか1項に記載のウイルスベクターをそれを必要とする患者に投与するステップを備える癌の診断方法。
- 請求項1~請求項20のいずれか1項に記載のウイルスベクターをそれを必要とする患者に投与するステップを備える癌の予防方法、転移抑制方法、又は治療方法。
- 更に、前記ウイルスベクターを患者の癌幹細胞に感染させるステップを備える、請求項26に記載の予防方法、転移抑制方法、又は治療方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013507161A JP5975352B2 (ja) | 2011-03-25 | 2012-03-23 | 癌幹細胞を標的とするウイルスベクター |
US14/007,227 US20140023619A1 (en) | 2011-03-25 | 2012-03-23 | Viral vector targeting cancer stem cells |
US16/045,246 US10662441B2 (en) | 2011-03-25 | 2018-07-25 | Viral vector targeting cancer stem cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011-068530 | 2011-03-25 | ||
JP2011068530 | 2011-03-25 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/007,227 A-371-Of-International US20140023619A1 (en) | 2011-03-25 | 2012-03-23 | Viral vector targeting cancer stem cells |
US16/045,246 Division US10662441B2 (en) | 2011-03-25 | 2018-07-25 | Viral vector targeting cancer stem cells |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012132369A1 true WO2012132369A1 (ja) | 2012-10-04 |
Family
ID=46930146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/002031 WO2012132369A1 (ja) | 2011-03-25 | 2012-03-23 | 癌幹細胞を標的とするウイルスベクター |
Country Status (3)
Country | Link |
---|---|
US (2) | US20140023619A1 (ja) |
JP (1) | JP5975352B2 (ja) |
WO (1) | WO2012132369A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2509388A (en) * | 2012-11-30 | 2014-07-02 | Ixogen Ltd | Oncolytic adenoviruses expressing E1B-156R isoform gene |
JP2014207883A (ja) * | 2013-03-27 | 2014-11-06 | 国立大学法人岡山大学 | がん幹細胞及びその用途 |
CN104263723A (zh) * | 2014-09-15 | 2015-01-07 | 南京医科大学 | 一种与原发性肺癌辅助诊断相关的低频高外显性遗传标志物及其应用 |
CN107513524A (zh) * | 2017-09-30 | 2017-12-26 | 中牧实业股份有限公司 | 一株猪塞内加谷病毒毒株及其应用 |
CN107760719A (zh) * | 2017-10-24 | 2018-03-06 | 胜武(北京)生物科技有限公司 | 柯萨奇病毒在过继免疫基因递送系统中的应用 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014153204A1 (en) | 2013-03-14 | 2014-09-25 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
KR20180112024A (ko) | 2016-02-23 | 2018-10-11 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현 |
CN110062630A (zh) | 2016-12-12 | 2019-07-26 | 萨克生物研究学院 | 肿瘤靶向合成腺病毒及其用途 |
US20190151383A1 (en) * | 2017-11-21 | 2019-05-23 | Faris Farassati | Signal-smart oncolytic viruses in treatment of human cancers |
CN111363726A (zh) * | 2018-12-26 | 2020-07-03 | 上海元宋生物技术有限公司 | 表达干扰素的溶瘤病毒及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005115476A1 (ja) * | 2004-05-25 | 2005-12-08 | Univ Kurume | サービビン(Survivin)プロモーターを含む増殖型ベクターを有効成分とする医薬 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050287120A1 (en) | 1997-03-21 | 2005-12-29 | Fisher Paul B | Cancer - targeted viral vectors |
US20050208466A1 (en) | 2002-06-17 | 2005-09-22 | Nagoya Industrial Science Research Institute | Method of selective isolation or visualization of target cells differentiated from embryonic cells or kit for visualization |
US7396680B2 (en) * | 2003-10-31 | 2008-07-08 | Cornell Research Foundation, Inc. | Stem cell-specific promoters and their use |
WO2010097419A1 (en) | 2009-02-25 | 2010-09-02 | Fundació Privada Centre De Regulació Genòmica (Crg) | Conditionally replicating adenovirus effective in the treatment of tumors |
-
2012
- 2012-03-23 WO PCT/JP2012/002031 patent/WO2012132369A1/ja active Application Filing
- 2012-03-23 JP JP2013507161A patent/JP5975352B2/ja active Active
- 2012-03-23 US US14/007,227 patent/US20140023619A1/en not_active Abandoned
-
2018
- 2018-07-25 US US16/045,246 patent/US10662441B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005115476A1 (ja) * | 2004-05-25 | 2005-12-08 | Univ Kurume | サービビン(Survivin)プロモーターを含む増殖型ベクターを有効成分とする医薬 |
Non-Patent Citations (2)
Title |
---|
CRIPE TP ET AL.: "Targeting Cancer-initiating Cells With Oncolytic Viruses", MOL THER., vol. 17, 2009, pages 1677 - 1682, XP055200299, DOI: doi:10.1038/mt.2009.193 * |
TABU K ET AL.: "Analysis of an alternative human CD133 promoter reveals the implication of Ras/ ERK pathway in tumor stem-like hallmarks", MOL CANCER., vol. 9, 2010, pages 39, XP021067990 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2509388A (en) * | 2012-11-30 | 2014-07-02 | Ixogen Ltd | Oncolytic adenoviruses expressing E1B-156R isoform gene |
GB2509388B (en) * | 2012-11-30 | 2015-04-29 | Ixogen Ltd | Oncolytic adenoviruses with increased levels of the E1B-156R isoform |
US10047347B2 (en) | 2012-11-30 | 2018-08-14 | Ixogen Ltd. | Oncolytic adenoviruses with increased proportion of the 156R splicing isoform of the E1B protein |
US10738283B2 (en) | 2012-11-30 | 2020-08-11 | Ixogen Ltd. | Oncolytic adenoviruses with increased proportion of the 156R splicing isoform of the E1B protein |
JP2014207883A (ja) * | 2013-03-27 | 2014-11-06 | 国立大学法人岡山大学 | がん幹細胞及びその用途 |
CN104263723A (zh) * | 2014-09-15 | 2015-01-07 | 南京医科大学 | 一种与原发性肺癌辅助诊断相关的低频高外显性遗传标志物及其应用 |
CN107513524A (zh) * | 2017-09-30 | 2017-12-26 | 中牧实业股份有限公司 | 一株猪塞内加谷病毒毒株及其应用 |
CN107513524B (zh) * | 2017-09-30 | 2021-02-09 | 中牧实业股份有限公司 | 一株猪塞内加谷病毒毒株及其应用 |
CN107760719A (zh) * | 2017-10-24 | 2018-03-06 | 胜武(北京)生物科技有限公司 | 柯萨奇病毒在过继免疫基因递送系统中的应用 |
CN107760719B (zh) * | 2017-10-24 | 2020-09-22 | 北京领柯生物科技有限公司 | 柯萨奇病毒在过继免疫基因递送系统中的应用 |
Also Published As
Publication number | Publication date |
---|---|
US20140023619A1 (en) | 2014-01-23 |
US10662441B2 (en) | 2020-05-26 |
JP5975352B2 (ja) | 2016-08-23 |
US20180346929A1 (en) | 2018-12-06 |
JPWO2012132369A1 (ja) | 2014-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5975352B2 (ja) | 癌幹細胞を標的とするウイルスベクター | |
US20210060101A1 (en) | Tropic cell based virotherapy for the treatment of cancer | |
JP5971599B2 (ja) | 制限増殖型アデノウイルス | |
JP6072414B2 (ja) | 腫瘍選択的e1aおよびe1b変異体 | |
US20110256524A1 (en) | Recombinant adenovirus comprising tissue-specific promoter and tumor-targeting trans-splicing ribozyme and uses thereof | |
Krump et al. | From Merkel cell polyomavirus infection to Merkel cell carcinoma oncogenesis | |
KR101429696B1 (ko) | 안전성 및 항암활성이 증가된 재조합 아데노바이러스 및 이의 용도 | |
KR102167934B1 (ko) | 재조합 아데노바이러스 및 이를 포함하는 줄기세포 | |
Yan et al. | Combination of E2F-1 promoter-regulated oncolytic adenovirus and cytokine-induced killer cells enhances the antitumor effects in an orthotopic rectal cancer model | |
JP2014523236A (ja) | 腫瘍溶解性強化B型ヒトアデノウイルスAd11突然変異体の構築とその応用 | |
Zhu et al. | Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma | |
Yang et al. | Experimental study on inhibition effects of the XAF1 gene against lung cancer cell proliferation | |
US9624476B2 (en) | Conditionally replicating adenovirus | |
CN111500632B (zh) | 表达st13和trail的溶瘤腺病毒构建及其应用 | |
US20240165175A1 (en) | Muc16 promoter containing virus | |
Robert et al. | Oncolytic Adenovirus for the Targeting of Paclitaxel-Resistant Breast Cancer Stem Cells | |
CN104195117A (zh) | 一种携带靶向分裂期磷蛋白1基因的小发夹rna的重组溶瘤腺病毒 | |
KR101153844B1 (ko) | Kras G12V RNA를 특이적으로 인지할 수 있는 트랜스-스플라이싱 그룹 I 리보자임 | |
Minna et al. | Immunohistochemical Characterization and Sensitivity to Human Adenovirus Serotypes 3, 5, and 11p of New Cell Lines Derived from Human Diffuse Grade II to IV Gliomas | |
Jacobsen et al. | Advances in Gene Therapy for Bladder Cancer | |
Nurmi | Comparing the efficiency of E3 and CMV promoters for adenoviral transgene | |
Ehrig | Effects of stem cell transcription factor-expressing vaccinia viruses in oncolytic virotherapy | |
Danda et al. | Targeted Expression of Suicide Gene by Tissue-Specific Promoter and MicroRNA | |
Pennington et al. | ASSOCIATION FOR ACADEMIC SURGERY | |
NZ622585B2 (en) | Conditionally replicating adenovirus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12765180 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2013507161 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14007227 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12765180 Country of ref document: EP Kind code of ref document: A1 |